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CHAPTER I 
INTRODUCTION 
Bone resorption is the process by which the organic and inorgan-
ic components of the skeleton are degraded and removed. Bone resorp-
tion, closely linked with bone formation, allows for growth, mainte-
nance and repair of the skeleton. The principal effector cell of the 
osteolytic process is the osteoclast, however bone forming cells, mono-
cytes, macrophages and their derivatives are capable of bone removal. 
The direct and/or indirect roles of these accessory cells in the 
physiological and pathological processes of osteolysis may be signifi-
cant. Because of its destructive potential to the organism, bone 
resorption is highly regulated. If this process dysfunctions due to a 
cellular or regulatory defect, bone loss may result either thoughout 
the skeleton as in osteoporosis or in a localized area as in rheumatoid 
arthritis. In either case the effects can be debilitating or life 
threatening. Although the effects of physiological and pathological 
bone loss are apparent, knowledge of the process, especially in the 
disease state, is limited and further investigation is necessary. 
Implantation of mineralized bone matrix into subcutaneous sites 
results in a rapid, cell-mediated osteolytic response (Glowacki et al., 
1981; Glowacki and Cox, 1986). Histological evaluation of the implant 
site revealed mononuclear and multinucleated giant cells (MNGC)s 
1 
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contacting the bone particles. Although it has been suggested that the 
MNGCs surrounding the bone surface are indeed osteoclasts, indicating 
this system can be used to study physiological bone resorption; it has 
been shown that MNGGs derived from the mononuclear phagocyte system 
also have osteolytic capabilities and may be present at the site 
(Walters and Schneider, 1985). Multinucleated giant cells are formed 
by fusion of mature mononuclear phagocytes in response to a foreign 
body infitrate or chronic inflammation (Adams, 1976). Sufficient 
evidence has not been presented to substantiate the use of this model 
system for physiological bone resorption. This model may be bet- ter 
suited for the study of pathological bone loss which is mediated by 
mononuclear and multinuclear phagocytic cells. In either case, this 
model system may be a valuable tool to study the osteolytic process. 
The osteoclast is both unique morphologically and functionally. 
However, other than the morphological features of multiple nuclei and 
ruffled borders, which are highly reliable but not always apparent in a 
histological section, there are few means of easily and quickly distin-
guishing osteoclasts from other bone cells and macrophages. Recently, 
the presence of tartrate resistant acid phosphatase (TRAP) in osteo-
clasts and their precursors has been used for identification in both 
normal and experimental situations. TRAP can be easily demonstrated, 
however the specificity of the enzyme to osteoclasts and the relia-
bility of using it in experimental situations have been questioned 
(Hattersley and Chambers, 1989). In the first study of this disserta-
tion, a method using image analysis was devised for quantitating TRAP 
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activity and defining a level which was specific for the osteoclast. 
To define the level of TRAP expression, osteoclasts from rat proximal 
tibiae and cells generated at the subcutaneous site of implanted miner-
alized bone matrix were reacted for TRAP and compared. This level of 
TRAP expression could be used to characterize osteoclasts in both nor-
mal and experimental situations. Previously, only the presence of the 
enzyme or a subjective evaluation of TRAP expression had been used. 
In the next study the subcutaneous bone implant was assessed as 
a model system for bone resorption. The influence of three prepara-
tions of bone matrix- mineralized, demineralized and a mineralized/ 
demineralized composite- on the recruitment of multinucleated giant 
cells to the implant site was investigated. The cells surrounding each 
of the three types of bone matrix were characterized using level of 
TRAP expression and ultrastructure as criteria. TRAP expression and 
ultrastructure of the MNGCs were compared to TRAP expression and ultra-
structure of normal osteoclasts. The final studies employed the use of 
hormones and a cytokine to modulate the cellular response to the three 
types of bone implants. The histochemical and morphological effects of 
these substances to modulate or to transform the MNGCs into osteoclasts 
at the site were determined. 
In summary, the primary goal of this investigation is a better 
understanding of the process of bone resorption through characteriza-
tion of the cells elicited by the implanted bone matrix. The osteoly-
tic potential of cells, other than osteoclasts, that are commonly pres-
ent and may be active in osteolytic disease states must be assessed to 
4 
determine their role in the process of pathological bone resorption. 
Clinically, bone implants and transplants are used extensively in 
corrective neurological and orthopedic surgeries and craniofacial 
reconstructive surgeries, mainly to promote localized bone formation. 
The extent of mineralization of a devitalized bone implant has a direct 
effect on its ability to form bone. The implant system described here 
may be used to evaluate the effectiveness and subsequent cell-mediated 
resorption of some clinical bone implants. It may also be used to as-
sess the direct role of monocytes and/or macrophages in pathological 
bone destruction. Characterization of the cells elicted to implanted 
bone matrix will determine whether the in vivo model system reflects 
osteoclastic resorption or monocyte-macrophage bone destruction, which 
has been implicated in osteolytic disease states. Bone resorption is a 
cell-mediated process, coupled with bone formation, which is able to 
precisely mold and define the form of the growing and fully developed 
skeleton. Most of the details of this process are yet to be eluci-
dated. 
CHAPTER II 
REVIEW OF REIATED LITERATURE 
Osteoclast Morphology and Function 
Ostoklast was the name given to the multinucleated cell found in 
the bone microenvironment. Based on circumstantial evidence, as early 
as 1852, Tomes and de Morgan proposed that bone resorption was a cell-
mediated process, however, they were unable to fully characterize the 
cells, the factors responsible for their occurrence, their distribution 
or regulation. Subsequent observations described the multinucleated 
cell in areas of bone loss but did not propose a function for it. 
Although the multinucleated cell of bone had been described over twenty 
years previously, the suggestion that bone removal was the principal 
function of the osteoclast was not proposed until 1872, by Kolliker 
when he named the cell. Since the osteoclast's identification, the 
mechanism of its function, its regulation and origin have been the sub-
jects of numerous investigations and controversies. 
The osteoclast can be distinguished from other types of multi-
nucleated giant cells by its location next to the bone surface and a 
combination of characteristic membrane specializations indicative of 
its function, bone removal. At the light microscopic level, the osteo-
clast is characteristically a large cell with multiple nuclei. Present 
in the area of bone removal, the osteoclast is found along the bone 
5 
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f e in cavities or pits called Howship's lacunae. The cytoplasm is sur ac 
. ble and can range from basophilic to acidophilic (Gothlin and 
var1a 
Ericsson, 1976). The definitive feature of an active osteoclast how-
r is the brush or striated border which is made up of fine cyto-eve , 
plasmic processes located along the bone-cell interface. 
Ultrastructurally, the morphological features of the osteoclast 
have been described in detail. As was seen at the light microscopic 
level, the most conspicuous features are the large size and multiple 
nuclei arranged in a cluster. However, the feature that morpholog-
ically defines the osteoclast is the ruffled border. The ruffled 
border, which is equivalent to the brush border at the light micro-
scopic level, is a specialized area of the cell membrane in contact 
with the bone surface. The ruffled appearance is due to an irregular 
complex system of cytoplasmic infoldings which exhibit a coated mem-
brane structure (Kallio et al., 1971). Subjacent to the ruffled border 
are vacuoles and vesicles, which have been shown to contain bone salt 
crystals. The ruffled border area has been implicated as the area of 
bone resorption based on the coated cell membrane, which may facilitate 
formation of the cytoplasmic vesicles, and the presence of bone salt 
crystals within vacuoles in the area subjacent to the ruffled border. 
Baron et al. (1985) have shown that the extracellular space bound by 
the ruffled border and the bone surface is actively acidified by the 
secretion of lysosomal enzymes by the osteoclast. Also, the extracel-
lular surface of the ruffled border membrane expresses a 100-kD protein 
similar or identical to those expressed in the limiting membrane of 
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secondary lysosomes and other acidified organelles. Antibodies to the 
100-kD protein cross-react with a proton-pump ATPase from pig gastric 
mucosa and may perform a similar function of acidification via proton 
transfer across the membrane. Another feature of the osteoclast, which 
is not exclusive but necessary for bone resorption, is the clear zone. 
The clear zone, as the name implies, is an organelle free zone, which 
contains actin and surrounds the ruffled border in an active cell. It 
may also be present in inactive osteoclasts and active macrophages and 
monocytes cultured with devitalized bone particles (King and Holtrop, 
1975; Teitelbaum and Kahn, 1980). The clear zone aids in the resorp-
tion process by anchoring the cell firmly to the bone substrate and 
isolating the active resorption site, the ruffled border area. The 
cell characteristically exhibits a high concentration of lysosomes and 
ribosomes. Mitochondria are also seen in large numbers, scattered 
throughout the cytoplasm except in the area of the ruffled border. An 
extensive Golgi apparatus is present around the clustered nuclei. 
Also, found in a clustered arrangement, are numerous centrioles, which 
form a centrosphere (Matthews et al., 1967). Prior to its identifica-
tion in foreign body giant cells, the centrosphere was believed to be 
an exclusive feature of the osteoclast (Sapp, 1976). The centrosphere 
has provided a plausible explanation for the lack of mitotic figures 
and formation of the osteoclast by cell fusion. Because of their 
clustered arrangement at a distance from the nuclei, the centrioles 
would probably not be avaliable for nuclear/cell division. 
Histochemically, the osteoclast can be characterized by.the 
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presence of a specific hydrolytic enzyme, the tartrate resistant form 
of acid phosphatase (TRAP). Acid phosphatases are lysosomal enzymes 
that have been classically divided into two groups, based on their 
sensitivity to tartrate. The tartrate sensitive isoenzyme has been 
identified in all animal cells except the erythrocyte (Anderson and 
Toverund, 1986). The tartrate resistant form has been identified in 
human leukocytes and more recently in bone (Li et al., 1970; Minkin, 
1982). TRAP has been proposed to be a marker for osteoclast differen-
tiation and function (van de Wijngaert and Burger, 1986; Minkin, 1982). 
Scheven et al. (1985) have shown the immediate osteoclast precursor is 
a mononuclear, nonproliferative cell exhibiting TRAP activity. Minkin 
(1982) observed significant increases in TRAP activity in the media of 
newborn mouse calvaria cultures which had been stimulated to induce 
bone resorption, relative to control cultures. 
Another biochemical marker proposed for characterization of the 
osteoclast is carbonic anhydrase. The function of this enzyme is to 
catalyze the reversible hydration of co2 . It can facilitate gas trans-
fer or produce H+ or HC03+ rich solutions. Gay and Mueller (1974) 
isolated carbonic anhydrase in chicken osteoclasts and suggested that 
its role in H+ secretion which could be directly linked to mineral 
resorption. Vaananen and Parvinen (1983) were able to identify the 
c-isoenzyme of carbonic anhydrase in rat calvarial osteoclasts. 
Carbonic anhydrase inhibition studies which showed successful inhib-
ition of bone resorption suggest a role for the enzyme in osteoclast-
mediated bone resorption. Administration of osteotropic hormones, 
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parathyroid hormone, calcitonin and 1,25 dihydroxyvitamin o3 , have been 
shown to influence either the location or the activity of carbonic 
anhydrase in osteoclasts in vitro (Cao and Gay, 1985; Hall and Kenny, 
1985). 
The function of the osteoclast as the effector of bone resorp-
tion was proposed over 100 years ago and was initially supported by 
histological evidence. The classic theory of the bone resorption 
process indicates that the osteoclast dissolves the bone mineral 
extracellularly by secretion of acid and chelating agents and then 
phagocytoses the resorption products, both inorganic mineral and organ-
ic matrix components (Sakamoto and Sakamoto, 1986). Although this 
theory has been accepted, there are areas of uncertainty and contro-
versy; specifically, the collagenolytic potential of osteoclasts and 
the sequence of events in the process. Bone mineral has been identi-
fied within the vacuoles of osteoclasts substantiating osteoclastic 
uptake of the inorganic components. However, bone collagen has not 
been seen within the osteoclast and investigators have used this to 
support the possible role of an auxillary cell responsible for the 
removal of the organic matrix components. Heersche (1978) proposed a 
combined effort by the osteoclast, responsible for the mineral dissolu-
tion, and a fibroblast or macrophage, responsible for organic matrix 
removal. Sakamoto and Sakamoto (1982) suggested that bone resorption 
occurs in two phases. The first phase involves enzymatic removal of 
matrix collagen by osteoblastic collagenase followed by a second phase 
of osteoclastic digestion of the bone crystal. However, Chambers et 
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al. (1984), using in vitro techniques, have shown the ability of the 
osteoclast to digest both components of the bone matrix. 
Hormonal Control of Bone Cell Function 
Osteoclastic formation and function is regulated directly and 
indirectly by a host of calcemic hormones, cytokines and growth fac-
tors. Calcemic hormones not only regulate the function of the cells 
responsible for bone remodelling but also play a role in calcium homeo-
stasis. Parathyroid hormone (PTH) and 1,25 dihydroxyvitamin n3 (1,25 
(OH) 2D3) have stimulatory effects on bone resorption, however receptors 
for these hormones have not been demonstrated on the osteoclast (Rou-
leau et al., 1986; Silve et al., 1982). The effects of PTH and 1,25 
(OH) 2D3) must therefore, be mediated by an indirect mechanism. When 
osteoclasts are mechanically removed from neonatal rat long bones and 
allowed to adhere to slices of cortical bone, excavation of the bone 
surface by the isolated osteoclasts begins within hours and can be 
quantified by scanning electron microscopic analysis of the bone 
surface. This technique forms the basis for a bioassay by which the 
effects of hormones on bone resorption can be assessed (Chambers et 
al., 1985). PTH and l,25(0H) 2D3 administration did not influence the 
resorption potential of the isolated osteoclasts (Chambers et al., 
1985). However, if the osteoclasts are cultured with either osteo-
blastic cell lines, primary cultures of osteoblasts or the supernatant 
from PTH or l,25(0H) 2n3 stimulated osteoblastic cells, the increase in 
resorption is 2 to 4 times that seen without hormone (McSheehy and 
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Chambers, 1986a; McSheehy and Chambers, 1986b). In vitro investiga-
tions using isolated osteoblasts and osteoclasts indicated that the 
activation of osteoclasts by PTH was dependent on the presence of 
osteoblasts. Rodan and Martin (1981) suggested a role for the osteo-
blast in physiological bone resorption based on identification of 
receptors and its responsiveness to the bone resorbing hormones. 
Qsteoblasts, which form a cellular barrier over the bone surface, have 
been shown to change their shape and uncover the bone surface in re-
sponse to PTH and prostanoids. The uncovered bone surface is then 
exposed to the osteoclasts for degradation. Also, osteoblasts secrete 
collagenase and increase the rate of collagenase secretion when stimu-
lated by PTH (Puzas and Brand, 1979; Sakamoto and Sakamoto, 1982). 
They are able to remove the unmineralized organic layer to expose the 
subjacent mineral (Chambers and Fuller, 1985). This is an important 
finding since it has been shown in vitro, that osteoclasts excavate the 
bone surface only if placed on a mineralized surface and were not able 
to excavate pits if placed on an unmineralized surface. 
PTH facilitates bone resorption in vivo by increasing (1) the 
number of osteoclasts; (2) the number of nuclei per cell, denoting an 
increase in formation by increased fusion; (3) the proportion of osteo-
clasts exhibiting ruffled borders; and (4) the extent of the ruffled 
border. In vivo, increases in osteoclast number in the rat rib have 
been detected as early as 30 minutes after the administration of PTH 
(Burger et al., 1986). An increased number of nuclei per cell has been 
documented to occur as early as 1 hour after PTH administration in kit-
12 
tens (Addison, 1979). Holtrop et al. (1979) demonstrated an increase 
in the average size of the ruffled borders, the clear zones and the 
cells after injection of SO U of purified bovine PTH. The effects of 
PTH on osteoclast function include increased synthesis and secretion of 
acid phosphatase and ~glucuronidase and increased acidity in the 
extracellular space bound by the ruffled border and bone. (Vaes 1965, 
1968; Anderson et al., 1985, 1986). 
It remains questionable whether PTH has an effect at the level 
of osteoclast differentiation. Fuller and Chambers (1987) incubated 
rabbit bone marrow cells or cells from neonatal rabbit spleen for up to 
4 weeks on plastic cover glasses and bone slices in the presence of 
PTH, l,2S(OH) 2n3 and interleukin-1 (IL-1) or a combination of these 
hormones and the cytokine. Using an osteoclast specific antibody 
(Horton et al., 1985) and the ability to excavate bone slices as 
criteria for osteoclast identification, osteoclasts were seen only in 
cultures of bone marrow or spleen incubated with l,2S(OH) 2n3 , indica-
ting PTH had no effect on differentiation in this culture system. 
Perris (1971) however, reported PTH administration in vivo stimulated 
mitosis in rat bone marrow, thymus and liver. This response to PTH was 
shown to be mediated by an increase in plasma calcium. In short 
term incubations with PTH stimulated rnitogenesis in hernopoietic stern 
cells (Gallien-Lartigne and Carrez, 1974). Since osteoclasts are of 
hernopoietic origin (Marks, 1983; Chambers, 1985), the increase in 
osteoclast number seen with PTH administration may be a result of rnito-
genic stimulation of the bone marrow. 
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PTH has also been shown to reduce bone formation by directly 
affecting osteoblast activity. In vitro investigations revealed that 
the administration of the hormone reduced osteogenesis by inhibiting 
the synthesis and secretion of matrix proteins including collagen and 
osteocalcin, profoundly decreased citrate decarboxylation, and possibly 
inhibited alkaline phosphatase (Kream et al., 1980; Dietrich et al., 
1976; Lian and Canalis, 1985; Beresford et al., 1984; Luben and Cohn, 
1976; Luben et al., 1976). In vivo, PTH has been shown to cause both 
inhibition as an acute effect (Bingham et al., 1969) and stimulation as 
a long term effect (Tam et al., 1982). Intermittent exposure to low 
levels of hormone similar to the physiological release, produces in-
creased number and activity of osteoblasts. Recently, Slovik (1986) 
reported increased bone mass in osteoporotic patients with a treatment 
regimen of intermittent low doses of PTH and l,25(0H) 2D3 . Sustained 
exposure of PTH, both in vitro and in vivo, causes a catabolic response 
including reduced collagen synthesis and increased resorption by secre-
tion of plasminogen activator and collagenase (Hamilton et al., 1985). 
The effects of 1,25 dihydroxyvitamin o3 have not been fully 
characterized, however evidence has been presented in support of its 
role in both bone formation and resorption. Receptors for l,25(0H) 2o3 
have been detected only in osteoblasts and preosteoblasts (Kream et 
al., 1977; Manologas et al., 1979). Using isolated osteoclasts, 
Chambers and colleagues (Chambers and Fuller, 1985; Chambers et al., 
1985) have shown no effect of l,25(0H) 2o3 on cytoplasmic motility or 
bone resorption. However, l,25(0H) 2D3 has been shown to stimulate bone 
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resorption in vivo and in bone organ cultures. Administration of 1,25 
(OH)
2
n3 to l,25(0H) 2n3 deficient rats increased the number of osteo-
clasts (Yoshiki et al., 1974). As was the case with PTH, the effects 
of l,25(0H) 2D3 on osteoclast function may be mediated by another cell 
in the bone microenvironment, possibly the osteoblast. 
A number of studies on several tumor cell lines have shown that 
l,25(0H) 2n3 induces differentiation along the monocyte/macrophage path· 
way (Abe et al., 1981; Tanaka et al., 1983; Bar-Shavit et al., 1983; 
McCarthy et al., 1983). Differentiation promoting properties include 
enhanced adhesion to substrates, increased phagocytic activity includ-
ing degradation of bone particles, expression of moncyte/macrophage 
morphology, enzymes and cell surface antigenic determinants. Adminis· 
tration of l,25(0H) 2D3 to mouse alveolar macrophage cultures promoted 
the formation of macrophage derived multinucleated giant cells (Abe et 
al., 1981). If these data can be extrapolated, based on similarities 
between progenitors of monocyte/macrophage and osteoclasts, the results 
suggest that l,25(0H) 2n3 may promote the differentiation and fusion of 
osteoclast precursors. 
Long term bone marrow cultures with and without l,25(0H) 2D3 
administration have been shown to promote MNGC formation (Allen et al., 
1981; Testa et al., 1981; Ibbotson et al., 1984; Roodman et al., 1985; 
MacDonald et al., 1986, 1987). Originally the MNGCs formed in these 
cultures were believed to be osteoclasts however, the results from this 
system were easily misinterpreted since macrophage-derived MNGCs, which 
resemble osteoclasts, were also formed. Standard criteria for identi· 
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fication is essential, however osteoclasts generated in vitro may not 
necessarily express the same characteristics as those in vivo. Fuller 
and Chambers (1987) reported l,25(0H) 2n3 was essential for osteoclast 
differentiation but not for macrophage-derived MNGC formation in this 
system. Criteria for identification of osteoclasts in this investi-
gation included staining with an osteoclast specific monoclonal anti-
body and the most discriminatory characteristic, excavation of bone 
slices. The cells that met both criteria were often mononuclear or had 
few nuclei and were not the MNGCs that had been described in previous 
long term bone marrow investigations (Testa et al., 1981; Pharaoh and 
Heersche, 1985; Roodman et al., 1985). 
Bone formation and mineralization is also affected by the 
administration of l,25(0H) 2D3 . Continuous infusion of the hormone in 
normal, young mice promoted calcification of bone matrix (Reynolds et 
al., 1976; Marie et al., 1985). However, the opposite results have 
been reported in rats (Wronski et al., 1986). Rickets, a childhood 
disease of reduced mineralization due to reduced l,25(0H) 2o3 , is 
characterized by low levels of serum calcium and phosphate which are 
insuffient to promote mineralization. l,25(0H) 2D3 supplements which 
elevate serum calcium and phosphate to normal levels have been shown to 
correct the disease. The effects of l,25(0H) 2n3 on osteoblast activity 
are conflicting. In vivo infusion studies and organ cultures of fetal 
bone indicated decreased matrix apposition rates and inhibition of 
collagen synthesis respectively (Marie et al., 1985; Raisz et al., 
1978). Investigations using cultures of osteoblast or osteoblast-like 
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cells have indicated both stimulation and inhibition of activity 
(Haneji et al., 1983; Manolagas et al., 1981; Chen et al., 1983; Wong 
et al., 1977). Along with its effects on bone cells, l,25(0H) 2D3 may 
also play an immunoregulatory role which could indirectly influence 
bone resorption by regulating the synthesis and release of immune cell 
products known to affect bone remodelling (Bhalla et al., 1986; Holder 
et al., 1985). The complex effects of l,25(0H) 2D3 suggest its possible 
role in the linking mechanism between bone formation and resorption. 
Unlike PTH and l,25(0H) 2D3 which have stimulatory effects and 
act in an indirect fashion on osteoclast activity and formation, 
calcitonin (CT) has been shown to have a direct inhibitory effect on 
the osteoclast. To substantiate the direct mechanism, CT receptors 
have been identified on the rat osteoclast in using 125r labelled 
salmon CT (Warshawsky et al., 1980). Within minutes of administration 
of CT to isolated osteoclasts, morphological changes have been exhib-
ited (Chambers and Magnus, 1982). Anderson et al. (1982) have shown CT 
specifically affects carbonic anhydrase activity, and Hunter et al. 
(1988) have demonstrated a general reduction in cellular acidity in 
response to CT. Akisaka and Gay (1986) demonstrated detachment of the 
osteoclast from the bone surface with CT-inhibited Na+,K+·ATPase 
activity localized in the ruffled border. In osteoclasts, CT acts by 
inhibiting cell movement and membrane ruffling (Baron and Vignery, 
1982). The effects of the hormone on mature osteoclasts either PTH-
stimulated or unstimulated are profoundly inhibitory, however a tran-
sient nature of the inhibitory effect on bone resorption in vitro, a 
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phenomenon termed escape, has been documented (Raisz et al., 1967; 
Wener et al., 1972; Tashjian et al., 1978; Feldman et al., 1980). 
These investigators suggested the escape mechanism may be due to a 
change in responsiveness to CT of the bones themselves. When CT and 
PTH are administered to bone organ cultures a reduced number of osteo-
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clasts and reduced Ca release was observed within the first 24 hours. 
However, after another 24 hours, the values for both parameters recov-
ered to an elevated level similar to cultures treated with PTH alone 
(Feldman et al., 1980; Tashjian et al., 1978). The transient inhibi-
tion may be at the level of recruitment and fusion. 
The inhibitory effects of CT on bone resorption have been well 
documented, although CT has also been shown to influence bone forma-
tion. The hormone has been localized in rat and mouse osteoblasts 
(Morel et al., 1985; Boivin et al., 1987). Using a demineralized bone 
matrix implant as a model for chondrogenesis and osteogenesis, CT 
promoted osteogenesis if administered during the initial phases of bone 
formation due to increased proliferation of cartilage and bone precur-
sors. However, when CT was administered after the onset of osteogen-
esis, subsequent bone formation was suppressed (Weiss et al., 1981). 
Local Control of Bone Cell Function 
Regulation of bone function as previously described has been of 
systemic origin. More recently, attention has been turned to the sub-
ject of local control by cytokines. Cytokines are soluble proteins 
produced by a variety of cells that can modulate the activity of the 
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cells that produce them and other cells. The effects of cytokines in 
bone became apparent after the number of osteoclasts was increased in 
rat bone organ cultures treated with a factor produced by mitogen-
activated peripheral blood mononuclear cells (Horton et al., 1972; 
Raisz et al., 1975). Originally thought to be one factor, it was 
determined that osteoclast activating factor (OAF) is a family of 
cytokines that possess OAF activity, including interleukin-1 (IL-1), 
the most potent, tumor necrosis factor-a (TNFa), and TNF-s. 
IL-1 has been shown to be a potent stimulator of bone resorption 
in two organ culture systems, the fetal rat long bone system and the 
neonatal mouse calvariae system. Bone resorption in both assays is 
quantified by 45ca release into the medium from prelabelled bones. In 
both assays system, 45 ca release increased with increasing concentra-
tions of IL-1 (Dewhirst et al., 1987; Sato et al., 1986; Gowen and 
Mundy, 1986; Heath et al., 1985). Bone resorption occured in response 
to IL-1 in organ culture systems, but not when isolated osteoclasts 
were treated with IL-1 (Thomson et al., 1986). IL-1 stimulated 
isolated osteoclasts only when osteoclasts were cultured with osteo-
blasts, osteoblast-like cells or the supernatant of stimulated osteo-
blasts. Like other mediators of osteoclastic bone resorption, IL-1 
stimulation of osteoclasts occurs indirectly. IL-1 has also been shown 
to have synergistic bone resorptive effects with PTH and other cyto-
kines (Stashenko et al., 1987; Dewhirst et al., 1987; Lorenzo et al., 
1988). This synergistic response between cytokines or the combination 
of cytokine and hormone suggests complex regulation is mediated by both 
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local and systemic factors. 
In pathologic conditions that feature chronic inflammation, such 
as rheumatoid arthritis and periodontal disease, increased bone resorp-
tion occurs. Horton et al. (1972) proposed the possibility that infil-
trating immune cells release cytokines that act locally and stimulate 
bone resorption. More specifically, Gowen et al. (1983) suggested a 
role for IL-1 in the pathogenesis of inflammatory disorders in which 
large numbers of monocytes/macrophages are present at osteolytic sites. 
IL-1 has been detected in the joint effusions from patients with 
rheumatoid arthritis where pathological bone loss occurs (Miyasaka et 
al., 1988). IL-1 may play a critical role in both physiological and 
pathological bone loss. 
Two other cytokines that stimulate and inhibit bone resorption 
repectively are TNF and interferon~ . TNF-a and TNF-8 have been shown 
to stimulate osteoclastic bone resorption along with the inhibition of 
bone formation in the fetal rat long bone and neonatal mouse calvariae 
(Bertolini et al., 1986; Deitrich et al., 1976). As was the case with 
IL-1, stimulation of bone resorption by TNF is indirect (Thomson et 
al., 1987). Interferon-y does not possess OAF activity and has been 
shown to inhibit both hormone and cytokine stimulated bone resorption 
(Gowen et al., 1986). 
Growth factors have also been shown to be possible mediators of 
bone cell development and/or function. Transforming growth factors 
(TGF)s, which had originally been described as factors that induce neo-
plastic changes on normal cells, have been shown to affect bone cell 
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function. TGF-S stimulates bone resorption, DNA and collagen synthesis 
in cultures of fetal rat calvariae (Centrella et al., 1986) and colla-
gen synthesis and alkaline phosphatase in rat osteosarcoma cells 
(Pfeilschifter et al., 1987). TGF-s~like activity is produced by bone 
and released during the resorption process (Pfeilschifter and Mundy, 
1987). Release of TGF-S during resorption and its stimulatory effects 
on osteoblasts, indicate TGF-S may play a role in the coupling of bone 
formation to resorption. 
The Origin of the Osteoclast 
The osteoclast can be distinguished from osteogenic bone cells 
not only by its morphology but also by its origin. A variety of 
experimental methods, including parabiosis and transplantation of bone 
marrow and spleen cells, have indicated the local mesenchymal origin of 
osteogenic cells and the extraskeletal origin of the mononuclear 
precursors that fuse to form multinucleated osteoclasts (Gothlin and 
Ericsson, 1973; Walker, 1975; Marks and Schneider, 1978, 1982). The 
identity of the precursor has not yet been definitely established 
although three possible precursors have been proposed. The oldest 
theory is that the monocyte or macrophage are the direct precursors. 
Various studies have demonstrated labelled osteoclasts after labelling 
peripheral blood leukocytes (Fischman and Hay, 1962; Jee and Nolan, 
1963). Zabonin-Zallone et al. (1984) have also shown fusion of iso-
lated monocytes with multinucleated cells in 5 day cultures of isolated 
osteoclasts. However, there are significant differences between osteo-
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clasts and monocytes and macrophages. Macrophages, monocytes and 
multinucleated phagocytes do not exhibit the hallmark characteristic of 
osteoclastic bone resorption, namely the ruffled border (Kahn et al., 
1978; Rifkin et al., 1979). Osteoclasts lack the characteristic 
membrane receptors, Fe and C3, and specific surface antigens character-
istics of the mononuclear phagocyte lineage (Hogg et al., 1980; Horton 
et al., 1984, 1985a, 1985b). Recent organ culture studies indicate 
that osteoclasts will develop from precultured bone marrow mononuclear 
phagocytes only in the presence of live bone and will resorb only live 
bone whereas devitalized bone is most likely resorbed by macrophages 
which are able to multinucleate in response to a number of stimuli 
(Burger et al., 1984). Also infusions of macrophage or monocyte/ 
macrophage precursors are incapable of restoring osteoclastic bone 
resorption in osteopetrotic mutants (Schneider and Byrnes, 1983; 
Schneider and Relfson, 1988). The monocyte/macrophage would therefore 
be an unlikely candidate for the osteoclast precursor. Burger et al. 
(1982) have recently shown that only the young, proliferating, weakly 
adherent mononuclear cells from the bone marrow can differentiate into 
osteoclasts. Their conclusion was monoblasts or promonoblasts are the 
more likely candidates for precursor to the osteoclast. 
The last possible theory is that the hemopoietic stem cell gives 
rise to a separate differentiation line. This is based on the inabil-
ity murine and human osteoclasts to interact with antibodies specific 
for monocytes and granulocytes (Loutit and Nisbet, 1982; Horton et al., 
1984, 1985a, 1985b). Also, transplantation of normal pluripotent 
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hemopoietic stem cells into a histocompatable osteopetrotic recipient 
resulted in removal of the excess bone characteristic of osteopetrosis 
and the production of phenotypically normal osteoclasts (Schneider et 
al., 1986). 
The Osteoclast and the Mononuclear Phagocyte System 
The osteoclast, because of a putative common lineage and 
functional and morphological similarities, has been closely associated 
with the cells of the mononuclear phagocyte system (MPS). The MPS is 
composed of hemopoietic precursor cells, promonocytes, circulating 
monocytes and tissue macrophages and their derivatives including macro-
phage polykaryons (van Furth et al., 1972). Macrophage polykaryons or 
multinucleated giant cells (MGC) are commonly found at inflammatory 
sites. They are formed by fusion of mononuclear phagocytes and they 
may possess from 2 to more than 200 nuclei. Two types of giant cells 
can be identified based on nuclear arrangements, however they may be 
variant phases of the same cell. The foreign body giant cell (FBGC) 
type has nuclei dispersed throughout its cytoplasm while the Langhans 
type exhibits a circular or semicircular arrangement of nuclei around 
the cell periphery (Chambers, 1978). The cell types are not specifical-
ly responsive to particular agents and both can be observed at the same 
inflammatory site. Mariano and Spector (1973) observed both cell types 
in response to subcutaneously implanted glass coverslips. Initially, 
only foreign body giant cells were observed but by 7 days the Langhans 
cells were more frequently seen. Cytochemical and ultrastructural 
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analysis of the Langhans cell revealed increased levels of acid 
phosphatase and succinic dehydrogenase and a highly developed Golgi 
apparatus as compared to FBGCs. A general morphological profile 
includes oval euchromatic nuclei, abundant cytoplasm, lysosomes and 
plasma membrane ruffling. Cells of the MPS and osteoclasts are con-
cerned with the removal of biological matter and are equipped with the 
necessary organellar machinery needed to accomplish their function 
(Chambers, 1978). From a phylogenetic point of view, the mononuclear 
phagocyte and its derivatives are a primitive form of defense. Compar-
atively, the osteoclast is a relatively new cell, developing with the 
evolution of the internalized bony skeleton. Cells of the MPS perform 
critical roles such as phagocytosis and antigen presentation in immune 
and foreign body responses. The osteoclast has not been seen to func-
tion in this manner. However, mononuclear phagocytes have been shown 
to have osteolytic capacity. 
The possible role of the mononuclear phagocyte in the process of 
bone resorption has recently become apparent. Monocytes and macro-
phages are often seen at the sites of rheumatoid arthritis, periodontal 
disease, and tumors that metastasize to bone. Although osteoclasts are 
principally responsible for physiological bone resorption, mononuclear 
phagocytes may also function directly in bone resorption, or indirectly 
by stimulating osteoclastic activity. Organ culture studies using 
fetal rat long bones indicated the products of resorbing bones have a 
chemotactic effect on human blood monocytes (Mundy et al., 1978). 
Evidence has also been presented to substantiate the direct ability of 
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phagocytes to degrade devitalized bone in vitro (Kahn et al., 1978; 
Mundy et al., 1977; Teitelbaum et al., 1979). Kahn et al. (1978) have 
shown that the resorbing monocytes develop osteoclastic characteris-
tics, clear zones and the release of acid phosphatase at the bone-cell 
interface. Fallon et al. (1983) showed macrophage polykaryons exhib-
ited an increased osteolytic capacity compared to their mononuclear 
counterparts. They proposed the fusion of cells has a physiological 
significance which in osteoclasts and macrophage polykaryons, is 
directly related to bone resorption. Another study substantiating the 
ability of mononuclear cells to resorb bone in vitro indicated an 
increase in 45ca release with the administration of !.:_ coli lipopoly-
saccharide to bone cultures but no effect with PTH or CT, indicating 
the mononuclear activity was modulated by inflammatory mediators and 
not by osteotropic hormones (McArthur et al., 1980). Rifkin et al. 
(1980) reported similar results in cultures of fetal rat long bones. 
Mononuclear cells were capable of osteoid ingestion and this ingestion 
was unaffected by administration of inhibitors of osteoclastic resorp-
tion. In vitro studies using monocytes obtained from patients suf-
fering from juvenile rheumatoid arthritis exhibited significantly 
45 greater Ca release from cultured calvariae when compared to normal 
age-matched patients (Key et al., 1986). These studies indicate the 
possible involvement of monocytes in the bone degradation process of 
rheumatoid arthritis. Mononuclear phagocytes and their derivatives may 
play an essential, direct and independent role in the physiological 
and/or pathological processes of bone resorption. 
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Although there is no direct evidence of monocyte or macrophage 
fusion to form osteoclasts or a relationship between multinucleated 
phagocytes and osteoclasts, the putative ontogenic relationship and 
morphological and functional similarities between these cells have 
provided a basis for the use of macrophages, monocytes and multinu-
cleated phagocytes in studies of osteoclastic bone resorption (Teitel-
(baum and Kahn, 1979). However, along with the similarities that 
exist, there are important differences between osteoclasts and the 
cells of the MPS that prohibit the use of macrophages, monocytes and 
multinucleated phagocytes as osteoclast surrogates in experimentation. 
The ability of mononuclear and multinuclear phagocytes to degrade bone 
matrix may suggest a role, separate and distinct, from the osteoclast 
in the normal versus the pathological processes of bone resorption. 
The Ectopic Bone Implant System 
Implantation or transplantation of live mineralized bone or 
devitalized, demineralized bone at an ectopic site has become a common 
model system for osteogenesis, or bone formation (Reddi and Huggins, 
1972). The effect of the substrate specificity became apparent with the 
development of an in vivo implantation model for bone resorption using 
devitalized, mineralized bone matrix (Glowacki et al., 1981). Devital-
ized, mineralized bone matrix which was implanted into calvarial de-
fects or a subcutaneous site resulted in a rapid response of cell-
mediated bone resorption. Histological evaluation of the implant site 
revealed mononuclear and multinuclear phagocytes surrounding the bone 
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particles. Functional analysis indicated bone removal had occurred. 
Therefore, the mineral content of the implant determines the initiation 
of either bone resorption or bone formation and may have clinical 
implications in reconstructive or corrective surgery where bone im-
plants are readily used. In the calvarial defect model, the elicited 
cells seen may have migrated from the neighboring bone but in the 
subcutaneous model the implant is isolated from the normal bone cell 
populations. Although it is proposed that the multinucleated giant 
cells surrounding the bone surface are indeed osteoclasts (Glowacki et 
al., 1981; Glowacki and Cox, 1986; Glowacki et al., 1986), similar 
studies are not able to substantiate these results and characterize 
these cells as multinucleated giant cells or macrophage polykaryons 
(Walters and Schneider, 1985, 1987, 1988; Dvonch and Schneider, 1986; 
Popoff and Marks, 1986). Multinucleated giant cells are commonly found 
at inflammatory sites. Chronic inflammation or granulomatous inflam-
mation is a response induced by infective agents, foreign bodies or 
physical irritants. These responses, characterized by a collection of 
mature mononuclear phagocytes, result because of the persistent and 
often particulate nature of the foreign body or irritant that has 
resisted destruction by an acute inflammatory reaction. In this model 
system the particulate and indestructable nature of the bone implant 
may provoke a granulomatous inflammatory response. Therefore, further 
investigation is needed to characterize these multinucleated giant 
cells at the site of the implant before this subcutaneous bone implant 
can be used as a model for osteoclastic bone resorption or monocyte/ 
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macrophage bone destruction. 
CHAPTER Ill 
QUANTIFICATION OF TARTRATE RESISTANT ACID PHOSPHATASE 
ACTIVITY USING A COMPUTERIZED IMAGE ANALYSIS SYSTEM 
ABSTRACT 
Tartrate resistant acid phosphatase (TRAP) is a hydrolytic 
enzyme that has been associated with bone resorption and has been 
accepted as a marker for identification of osteoclasts. The ease with 
which this enzyme can be demonstrated, combined with specific morpho-
logical features, creates a quick method for identifying osteoclasts in 
normal, pathological and experimental conditions. Recently, the speci-
ficity and reliability of the enzyme as a marker has been questioned 
since other cells have been shown to express TRAP. In this study I 
have developed a method for quantitating TRAP using an image analysis 
system and have identified a level of the enzyme specific to osteo-
clasts which can be used to differentiate osteoclasts from other cells 
capable of TRAP expression. TRAP expression characteristic to the 
osteoclast was compared with that expressed by multinucleated giant 
cells (MNGC)s recruited to the site of subcutaneously implanted miner-
alized bone matrix. Two weeks post-implantation, the pellets were re-
moved and processed for the demonstration of TRAP along with rat prox-
imal tibiae. Using image analysis, the density and distribution of the 
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enzyme could be determined. A high level of TRAP was consistently 
expressed by the in situ osteoclasts. The MNGGs associated with the 
mineralized bone implants expressed little if any TRAP reaction pro-
duct. TRAP levels from the mineralized implant associated MNGGs were 
significantly different (p< 0.05) from the level of expression by 
tibial osteoclasts. Using this system, the amount of TRAP reaction 
product or any other enzyme reaction product expressed can be objec-
tively and reproducibly quantitated. In this investigation, I have 
developed a method which identified a high level of TRAP expression 
specific to the osteoclast and this can be used to differentiate 
osteoclasts in other normal and experimental situations. 
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INTRODUCTION 
Tartrate resistant acid phosphatase (TRAP) has been widely 
accepted as a cytochemical marker for the osteoclast and its precursors 
(Scheven et al., 1986; van de Wijngaert and Burger, 1986; van de 
Wijngaert et al., 1987; Hammerstrom et al., 1971). The presence of the 
enzyme and other morphological features like multiple nuclei and the 
cell's location along the bone surface allow for quick and easy identi-
fication of the osteoclast in the normal microenvironment of bone. 
TRAP is relatively specific for osteoclasts but the enzyme has been 
identified in osteoblasts, osteocytes, hairy cells, alveolar macro-
phages and activated macrophages in normal and pathological states 
(Bianco et al., 1987;1988; Cole and Walters, 1987; Ketchum et al 1985; 
Efstratiadis et al., 1985; Razdun et al., 1983; Snipes et al., 1986). 
Osteoclasts are not a product of macrophage or osteoblast fusion and 
the presence of TRAP in macrophages, macrophage derived multinucleated 
giant cells (MNGC)s or osteoblasts is probably not an indication of 
their ability to differentiate into osteoclasts. Morphological and 
histochemical similarities between the osteoclast and MNGCs and/or 
macrophages may create problems in identification of osteoclasts in 
experimental systems where both may be present. The precise function 
of TRAP is unknown but it is a hydrolytic enzyme related to the process 
of bone resorption. 
In an attempt to study the ontogeny, behavior and function of 
the osteoclast, in vitro and in vivo model systems have been developed 
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which employ TRAP as a means of osteoclast identification. Two in 
vitro systems have been extensively studied. In the first system, 
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periosteal free, 17 day old fetal metatarsals from the mouse, which do 
not develop osteoclasts on their own, can serve as a live substrate to 
induce development of osteoclasts when cocultured with osteoclast 
precursors (Burger et al., 1982). In this model system osteoclasts and 
their immediate mononuclear precursors have been identified using TRAP 
and morphological critieria. 
In a second popular in vitro model system, large multinucleated 
cells, originally thought to be osteoclasts were generated in long term 
cultures of bone marrow mononuclear cells. These cells were presumed 
osteoclasts based on multiple nuclei, morphology and presence of TRAP 
(Ibbotson et al., 1984; Roodman et al., 1985; Takahashi et al., 1987). 
It has recently been questioned whether these cells are osteoclasts or 
MNGCs, since both can be generated in these cultures (Fuller and 
Chambers, 1987; Hattersley and Chambers, 1989). Whether or not osteo-
clasts can be generated in these cultures is not questioned but whether 
all MNGCs that are generated are osteoclasts. 
Other than transplant studies using mutant animals (Schneider 
and Byrnes, 1983; Schneider, 1985; Marks and Schneider, 1978), there 
are few models for the study of osteoclasts in vivo. Subcutaneous 
implantation of devitalized, mineralized bone particles, which was 
originally thought to elicit a MNGC response after 12 days, more 
recently has been proposed as a system to elicit osteoclasts (Glowacki 
et al., 1981; Glowacki et al., 1986; Glowacki and Cox 1986). Others 
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believe the response is not osteoclastic but an inflammatory response 
eliciting foreign body giant cells (Walters and Schneider, 1985, 1988; 
Holtrop et al., 1982; Popoff and Marks, 1986; Schmitz et al, 1986). In 
some of these investigations TRAP was employed to aid in proving or 
disproving the presence of osteoclasts. In a study by Glowacki et al., 
(1986) not only was the presence of TRAP in MNGCs adjacent to bone 
particles, polyetheyline particles and polymethylmethacrylate particles 
acknowledged, but the intensity of the reaction product was scored. 
Walters and Schneider (1988) also scored and compared the intensity of 
TRAP expressed by osteoclasts and MNGCs elicited by subcutaneously 
implanted bone and suture. These were the first attempts to use the 
level of TRAP reaction product expressed to characterize a cell. The 
purpose of this investigation was to devise a method to objectively and 
reproducibly quantitate and compare the levels of TRAP expression in 
multinucleated giant cells elicited by a mineralized bone implant and 
in situ osteoclasts. By quantitating the level of TRAP expression, the 
level of intensity characteristic of the osteoclast may be determined. 
This quantitation of TRAP is a more specific marker than the presence 
or absence of the enzyme. MNGCs other than osteoclasts may express 
TRAP but the level of TRAP expression may differ from that of the 
osteoclast. This is the first attempt to standardize the method of 
analysis. 
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MATERIAL AND METHODS 
Animals: These studies were performed using Norway-hooded Long Evans 
rats (Harlan Labs, Indianapolis, IN). All animals were maintained and 
used according to the recommedations in the Guide for the Care and Use 
of Laboratory Animals and the Guidelines of the Institutional Animal 
care and Use Committee at Loyola University Medical Center. 
Mineralized bone implant: Tibiae and fibulae were removed from 4-8 wk 
old Norway-hooded Long Evans rats. The soft tissue and cartilagenous 
epiphyses were removed and the marrow cavities were flushed with dis-
tilled water. The cleaned diaphyses were washed overnight in distilled 
water then extracted with absolute ethanol (30 min) and anhydrous ether 
(30 min). The bones were dried, pulverized with a mortar and pestle 
and sieved to yield particles 75-250 um in diameter. Sterile water was 
added to samples to create cohesive pellets of bone particles that 
could be easily implanted subcutaneously. The pellets were air dried 
and sterilized by U.V. radiation. 
Implants: Five wk old male Norway-hooded Long Evans rats (n=6) were 
anesthetized with chloral hydrate (400 mg/kg). Dorsal, upper thoracic 
incisions were made bilaterally and subcutaneous pockets were created. 
Each animal received a bone implant. The incisions were sutured and 
treated with betadine. Two wks post-implantation, the animals were 
sacrificed via ether inhalation, and the implants were carefully 
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excised. A 3 wk old rat was also sacrificed and the proximal tibia 
removed. 
Mophological and Histochemical Analyse~: The implant and a sample of 
proximal tibia were immediately fixed in cold 2.5% glutaraldehyde, 
0.1 M cacodylate buffer (pH 7.2) with 7% sucrose for 3 hrs, dehydrated 
in ascending concentrations of cold acetone and embedded in JB-4. 
Three micron sections were cut and allowed to adhere to gel-coated 
slides in the cold for 5 days. Tartrate resistant acid phosphatase 
activity was demonstrated using the Cole and Walters (1986) technique 
and 50 mM (L+) tartaric acid, however, the samples were not decal-
cified. Control sections were incubated without substrate. Twenty 
cells from each of sample were analyzed. 
Image Analysis of TRAP: The level of intensity of the TRAP reaction 
product in multinucleated giant cells located along the bone surface 
was analyzed using a computerized imaging system. The image was col-
lected using a Dage MTI 68 series video camera attached to the Leitz 
Orthoplan 2 light microscope. The image was processed using the Colo-
rado Video digitizer 270A and Priceton Gamma Tech (PGT) Imagecraft 
System 4+, run on a Digital Equipment Systems PDPll/73 using PGT 
Imagecraft (Figure 1). The sections were examined and the field of 
interest was displayed on a television monitor (Figure 2). To ensure 
overall consistency, a wire mesh grid was used as a standard to create 
a reproducible range of intensity and contrast which would include the 
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Y scale range of reaction product and background. Inconsistencies gra 
in the counterstained background of the samples were further corrected 
by standardizing the background in each sample to the intensity of 
mineralized bone. Using samples of implants and tibia, the lowest 
level at which TRAP reaction product that could be detected was used as 
a starting point to establish 4 gray level ranges of TRAP reaction pro-
duct intensity. On the 256 gray level scale, high intensity reaction 
product(+++), composed level 0-100; moderate intensity reaction pro-
duct(++), composed level 102-150; low intensity reaction product(+), 
151-175 and absence of reaction product (0), 175-256. Computer 
generated colors were assigned to each of the pixel ranges (Figure 3). 
This color tablet was stored and used on all images. An image of the 
field in view was collected and displayed on the computer screen. Area 
fraction analysis based on this gray-scale palette was limited to the 
specific window containing the MNGC (Figure 4 & 5). A ratio of the 
percentages of the gray scale windows, generated by area fraction 
analysis was used to determine the final score for each cell. Cells 
were scored as expressing high levels (++), moderate levels (+) or 
absence of reaction product. If the percentage of the TRAP reaction 
product that scored for moderate intensity (gray level range 102-150) 
was l.5x more than the percentage of the TRAP reaction that scored for 
low intensity (gray level range 151-175), the cell was scored as high 
intensity. If the cell failed to meet these requirements, the cell was 
scored as moderate intensity. If the cell exhibited a percentage of 
less than 1 in the low intensity range (151-175), the cell was scored 
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as absence of reaction product. The cell was scored as very high 
intensity if the percentage value for the high intensity range (0-100) 
was Sx the moderate intensity percentage (102-150). All tibial 
osteoclasts exhibit a very high to high level of reaction product (+++ 
or ++) and these ranges were combined. Multiple linear comparisons 
within the implant group and with the tibial osteoclasts were performed 
using the Welsch's t'W test for multiple linear comparisons (Wilcox, 
1987). 
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RESULTS 
Active osteoclasts from the proximal tibia were identified as 
multinucleated cells exhibiting vacuolization of the cytoplasm adjacent 
to the bone surface. Tartrate resistant acid phosphatase reaction 
product was observed as red granules within the cells and extracellular 
staining of the bone matrix adjacent to the osteoclasts (Figure 6). 
All osteoclasts consistently exhibited the highest staining intensity. 
Each implant was surrounded by a fibrous connective tissue cap-
sule. At the site of the mineralized implant, large multinucleated 
cells were found in contact with the bone particles. The majority of 
the multinucleated cells in contact with the bone particles expressed 
either a low level of TRAP reaction product or absence of the enzyme 
(Figure 7). The average number of MNGCs from the implant group 
expressing high levels of TRAP was significantly different (p<0.05) 
than the average number of osteoclasts expressing high levels of TRAP 
the proximal tibiae (Figure 8). The enzyme was generally distributed 
throughout the cytoplasm but in some cells TRAP was localized along the 
bone apposed cell membrane. There was also a low level of nonspecific 
extracellualr staining that could easily be distinguished from 
intracellular reaction product. Other MNGCs that were present at the 
site and not in contact with bone particles also expressed low levels 
of TRAP. These cells were not analyzed. The enzyme expression in the 
population of MNGCs from the mineralized implants analyzed was 
significantly lower than the osteoclasts (Figure 8). 
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DISCUSSION 
This study describes a technique to assess the level of TRAP 
activity and localization in MNGCs and osteoclasts using digital analy-
sis. The presence of TRAP has contributed to the identification of 
osteoclasts in the normal microenvironment of bone and in experimental 
model systems which have been used to study bone resorption and osteo-
clast development and function (Burger et al., 1982; Walters and 
Schneider 1988; Glowacki et al., 1986; Ibbotson et al., 1984). The 
level of acid phosphatase activity and TRAP in particular, has been 
evaluated to determine the best fixation and demineralization proce-
dures and effects of various concentrations of inhibitors on various 
acid phosphatase positive cells (Liu et al., 1987; Hammarstrom et al., 
1971). Recently, in studies on bone resorption, the level of TRAP 
activity in MNGCs has been analyzed to indicate a difference between 
MNGCs and osteoclasts. Both Walters and Schneider (1988) and Glowacki 
et al. (1986) evaluated the level of TRAP in MNGCs recruited to subcu-
subcutaneously implanted bone and other substances. In the investi-
gation by Walters and Schneider (1988), TRAP activity in MNGCs elicited 
by bone and suture implants was scant and differed from the high levels 
expressed by tibial osteoclasts. Glowacki et al. (1986) claimed that 
MNGCs elicited to devitalized bone implants were seen with high levels 
of TRAP activity suggesting these MNGCs were osteoclasts. The TRAP 
activity in cells from the bone implant however, was not compared to in 
situ osteoclasts from bone. Each study was a subjective analysis of 
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TRAP activity. Regardless of the level of TRAP activity needed for a 
cell to be identified as an osteoclast, error may result in the repro-
ducible quantitative assessment of enzyme activity by an observer. In 
this investigation, the level of TRAP expression by the MNGCs from the 
mineralized bone implant was significantly different from the TRAP 
expressed by osteoclasts. The morphology of the MNGCs was also 
nonosteoclastic, (data not shown), indicating the cells elicited by the 
mineralized bone implants were not osteoclasts. 
In the system described here, levels of activity, which comprise 
a specific catagory defined by the investigator, are set and analysis 
is objective and reproducible. The image of the field of interest is 
collected and can be analyzed immediately or saved for future analysis. 
Images can be saved and displayed simultaneously with other fields for 
comparison. This system allows for detection of the enzyme intensity 
related to distribution. Ultrastructurally, acid phosphatase has been 
localized within the extracellular channels of the ruffled border of 
the osteoclast, the bone·cell interspace and the underlying degraded 
matrix (Lucht 1971; Doty and Schofield 1972). In this study TRAP was 
also localized in the bone apposed cytoplasm and extracellularly on the 
bone surface. 
Area fraction analysis can be performed on an entire digitized 
image or any part which is enclosed in a window. A window which is 
limited to the MNGC is analyzed. The area of the window closely 
approximates the area of the cell so that the percentages of gray level 
intensities corresponding to TRAP reaction product are only those from 
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the cell. This, however, was a close approximation since the shape of 
the cells is variable. For the type of analysis in this investigation, 
if a window could have been drawn enclosing a specific area dictated by 
the shape of the cell, analyzing the entire cell and no other part of 
the field would be ensured. 
This method of analysis may be applied to other investigations 
where analysis of intensity and distribution of reaction product is 
necessary. The specificity of TRAP to the osteoclast may need to be 
redefined in terms of the level of intensity expressed, especially in 
experimental model systems where other cells are capable of TRAP 
expression and multinucleation. Although 4 catagories were established 
in this study, the availability of 256 gray levels allows for more 
catagories consisting of smaller ranges and more specific levels of 
analysis. The established catagories however, were able to distinguish 
between levels of TRAP activity expressed by osteoclasts and implant-
elici ted MNGCs. TRAP is demonstrated using a variety of substrates and 
tissue preparation methods, although this analysis system would not 
standardize the method of demonstration it may standardize the method 
of assessment so that future investigations using similar techniques 
may be compared. 
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Figure 1. 
Computerized image analysis system for the quantification of 
intracellular TRAP reaction product. 
A 
B 
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A - Dage MTI 68 series video camera 
B - Leitz Orthoplan 2 light microsope 
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I 'It.. 
I 
I 
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C - General Electric model 4MV-09 video monitor 
D - Colorado Video Inc. video digitizer 270A 
E - Princeton Gamma Tech System 4+ 
Princeton Gamma Tech Imagecraft Software 
Digital Equipment Corp. PDP 11 /73 computer 
Figure 1 
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Figure 2. 
Digitized image of rat proximal tibia stained for TRAP activity. 
Osteoclast (arrows) along the bone (b) surface demonstrating 
intense reaction product. 
Figure 3. 
Color enhanced image of rat proximal tibia from Figure 2. Color 
enhanced gray level ranges highlight intensity and distribution of 
TRAP reaction product within the osteoclasts (arrows). 
Figure 4. 
Area of analysis is limited to osteoclast by creating a window 
around the cell. 
Figure 5. 
Color assigned gray level ranges (upper left) and histogram of 
gray level distribution from which area fraction analysis is 
computed. A numerical value is computed for amount of area 
occupied by each gray level range. 
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Figure 6. 
Section of a 3 week old rat proximal tibia demonstrating 
osteoclasts (arrows) along the bone (b) surface stained intensely 
with TRAP reaction product. x400 
Figure 7. 
Section of mineralized bone implant demonstrating absence of TRAP 
reaction product in MNGC (arrows) adjacent to bone particles (b). 
x425 
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Figure 8. 
TRAP expression in MNGCs elicited by mineralized bone implant (2wk 
post-implantation) and in situ osteoclasts. TRAP reactivity 
scored as high level(++), moderate level(+), or absence of 
reaction product (0). (mean ±SEM). 
*, significantly different than tibia(++), p<0.05. 
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CHAPTER IV 
A MORPHOLOGICAL AND HISTOCHEMICAL COMPARISON 
OF THE CELLS ELICITED BY 
ECTOPIC BONE IMPLANTS AND TIBIAL OSTEOCI.ASTS 
ABSTRACT 
Pellets of mineralized, demineralized and a composite mixture of 
mineralized and demineralized, devitalized bone particles were 
subcutaneously implanted on the dorsal body wall of young adult rats. 
Two wks post-implantation, the pellets were removed and processed for 
histochemical and morphological analyses. Rat proximal tibia was also 
processed for evaluation. The levels of tartrate resistant acid 
phosphatase (TRAP) activity in the multinuceated giant cells (MNGC) 
from each of the three implants and osteoclasts were assessed using an 
image analyzer. The osteoclasts from the proximal tibia and the 
majority of MNGCs from the demineralized implants demonstrated high 
levels of TRAP activity. MNGCs from the mineralized implants showed 
either a low level or absence of TRAP activity. Most MNGCs from the 
composite implants exhibited a low level of TRAP activity, however 
there was a population of cells that demonstrated a high level of 
reaction product, similar to that seen in the tibia and demineralized 
implant. Morphologically, osteoclasts from the proximal tibia and from 
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the osteogenic demineralized implant exhibited ruffled borders. A 
small population of MNGCs from the composite implant also revealed 
osteoclastic features. In summary, MNGCs from the mineralized implant 
did not exhibit a level of TRAP reaction product or morphology similar 
to osteoclasts, while the majority of cells from the demineralized 
implant and a subpopulation of the MNGCs elicited by the composite 
implant did demonstrate TRAP expression and morphology similar to 
osteoclasts. The ability to elicit cells expressing osteoclasts at an 
ectopic site may be more dependent on the presence of demineralized 
matrix than mineralized matrix. 
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INTRODUCTION 
Subcutaneous or intramuscular implantation of devitalized, 
demineralized bone matrix can induce osteogenesis at an extraskeletal 
site (Reddi and Huggins, 1972; Urist and Strates, 1970). The reproduc-
ible sequence of events that occurs in response to the implants is 
analogous to endochondral bone formation with new bone formation occur-
ring on days 10-11 and remodelling by osteoclasts, occurring on days 
12-18. Implantation of devitalized, mineralized bone matrix or a 
composite of mineralized/demineralized matrices at a subcutaneous or 
intramuscular site inhibits this inductive ability (Urist and Strates, 
1970). Early studies by Reddi and Huggins (1972) identified multinu-
cleated giant cells, rich in organic acids presumably for mineral 
dissolution, at the site of a mineralized matrix implant and proposed 
the presence of the mineralized matrix either alone or in combination 
with demineralized matrix inhibited osteogenesis. Resorption of 
implanted bone fragments was quantitated by histomorphometry and 
radioactive calcium release assays to indicate a cell-mediated osteo-
lytic response did in fact occur (Glowacki, 1982; Walters and 
Schneider, 1985). Whether the osteolytic response was osteoclast-
mediated was questionable. 
Implantation of devitalized, mineralized bone into a cranial 
defect produced a similar cell-mediated osteolytic response, and the 
multinucleated giant cells were identified as foreign body giant cells 
(Glowacki et al 1981; Glowacki, 1982; Holtrop et al., 1982). None of 
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the cells were characterized as osteoclasts because they did not 
demonstrate a ruffled border, the hallmark morphological feature of the 
osteoclast. It is probable that mononuclear and multinuclear phago-
cytes were responsible for the removal of bone, since in vitro studies 
have indicated that monocytes and macrophages are capable of resorbing 
devitalized mineralized bone (Mundy et al., 1977; Kahn et al., 1978; 
Teitelbaum et al., 1979; McArthur et al., 1980). In these investi-
gations, mononuclear phagocytes and their derivatives did not exhibit 
ruffled borders which are functionally linked to the export of hydro-
lytic enzymes and the uptake of degraded matrix components. Teitelbaum 
et al. (1979) proposed mononuclear phagocytes internalize and digest 
bone particles, a different mechanism of osteolysis than the osteo-
clastic resorption of bone extracellularly, which would explain the 
absence of the ruffled borders in these cells. Epitheliod and foreign 
body giant cells are mildly phagocytic and are seen in contact with the 
bone particles giving the impression of an osteoclastic mode of bone 
resorption. 
Even though osteoclasts were not identified in the ectopic bone 
matrix implantation system, it was pursued as a model for the study of 
bone resorption (Glowacki, 1982; Glowacki, 1983). This was in part due 
to the lack of model systems to study the osteoclast and the acceptance 
of cells of the mononuclear phagocyte system as surrogates because of 
their presumed common, if not direct, lineage (Kahn et al., 1978; 
Teitelbaum et al., 1979). Since these investigations a decade ago, a 
number of differences have been demostrated between cells of the mono-
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nuclear phagocyte system and osteoclasts (Chambers and Magnus, 1982; 
Horton et al., 1984; Hogg et al., 1980). Because of these differences 
and improvements in isolation techniques, the surrogate studies were 
abandoned and the osteoclast itself is used for study. The in vivo 
bone implant model however, was not abandoned and in a later study 
Glowacki and Cox (1986) generated osteoclasts that demostrated tartrate 
resistant acid phosphatase and ruffled borders. Other investigations 
have not substantiated these results (Walters and Scheider, 1985, 1988; 
Popoff and Marks, 1986). Therefore, there is conflicting evidence on 
the nature of the multinucleated giant cells (MNGCs) recruited to the 
subcutaneously implanted mineralized bone particles. In this investi-
gation, I have examined the morphology and level of TRAP expressed by 
the multinucleated giant cells recruited to devitalized mineralized, 
demineralized and a composite of mineralized/demineralized matrices 
implants 2 weeks post-implantation, and compared the elicited cells to 
osteoclasts from rat proximal tibia. 
The purpose of this investigation is to assess the ability of 
each of these three implants to generate osteoclasts that are similar 
in morphology and expression of TRAP to normal osteoclasts found in the 
proximal tibia. Although the implant composed of both mineralized and 
demineralized bone matrices is unable to induce osteogenesis the pres-
ence of both matrices may have an effect directly or indirectly on 
osteoclast recruitment. Not only will the presence or absence of TRAP 
be evaluated, but also the intensity of the reaction product, to fur-
ther discriminate between the high level of TRAP expressed by function-
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al osteoclasts and the low level of TRAP that has previously been 
demonstrated in multinucleated giant cells generated at the site of 
bone and suture implants (Walters and Schneider, 1988). If the multi-
nucleated giant cells recruited to the mineralized bone particles, in 
fact are osteoclasts, they should resemble in situ osteoclasts from the 
proximal tibia. 
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MATERIAL AND METHODS 
Animals 
These studies were performed using Norway-hooded Long Evans rats 
(Harlan Labs, IN). All animals were maintained and used according to 
the recommedations in the Guide for the Care and Use of Laboratory 
Animals and the Guidelines of the Institutional Animal Care and Use 
Committee at Loyola University Medical Center. 
Bone Powder Preparation 
Mineralized bone implant: Tibiae and fibulae were removed from 4-8 wk 
old Norway-hooded Long Evans rats. The soft tissue and cartilagenous 
epiphyses were removed and the marrow cavities were flushed with dis-
tilled water. The cleaned diaphyses were washed overnight in distilled 
water then extracted with absolute ethanol (30 min) and anhydrous ether 
(30 min). The bones were dried, pulverized with a mortar and pestle 
and sieved to yield particles 75-250 um in diameter. Sterile water was 
added to samples to create cohesive pellets of bone particles that 
could be easily implanted subcutaneously. The pellets were air dried 
and sterilized by ultraviolet (U.V.) radiation. 
Demineralized bone implant: The mineralized bone powder prepared above 
was treated with 0.5 N HCl, 25 meq/gm (demineralizing agent) for 3 hrs. 
followed by repeated washings of cold deionized water to thoroughly 
remove the acid, absolute ethanol (30 min) and anhydrous ether (30 
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min). Sterile water was added to samples of demineralized bone to 
create pellets. The pellets were air dried and sterilized by U.V. 
radiation. 
Composite implant: A mixed bone powder implant was created from 25 mg 
mineralized bone powder and 5 mg demineralized bone powder. Sterile 
water was added to the mixture of the two powders to create cohesive 
pellets which were air dried and sterilized by U.V. radiation. 
Implants 
Six 5 wk old male Norway-hooded Long Evans rats were anes-
thetized with chloral hydrate (400 mg/kg). Dorsal, upper thoracic 
incisions were made bilaterally and subcutaneous pockets were created. 
One bone powder pellet was placed in each subcutaneous pocket and the 
incisions were sutured and treated with betadine. Each animal received 
one of each of the three types of bone implants. Two wks. post-
implantation, the animals were killed via ether inhalation, and the 
implants were carefully excised. 
Morphological and Histochemical Analyses 
One half of the specimen was immediately fixed in 4.0% glutar-
aldehyde, 0.1 M cacodylate buffer (pH 7.2) for 24 hrs, post-fixed in 1% 
osmium tetroxide, dehydrated in ascending concentrations of ethanol, 
and embedded in Epon 812. One micron sections were cut and stained 
with toluidine blue and evaluated by light microscopy. Thin sections 
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(60-70 run) were cut and stained with uranyl acetate and lead citrate 
for ultrastructural analysis using the Hitachi H600 electron micro-
scope. 
The remaining half of each specimen was immediately fixed in 
cold 2.5% glutaraldehyde, 0.1 M cacodylate buffer (pH 7.2) with 7% 
sucrose for 4 hrs, dehydrated in ascending concentrations of cold 
acetone and embedded in JB-4. Proximal tibiae were removed from 3 wk 
old Norway black-hooded Long Evans rats and also prepared as above. 
Three micron sections were cut and allowed to adhere to gel-coated 
slides in the cold for 5 days. Alternate sections were stained for 
tartrate resistant acid phosphatase activity using 50 mM L(+)-tartaric 
acid or for mineral content using the von Kossa technique (Humason, 
1962). Tartrate resistant acid phosphatase activity was demonstrated 
using the Cole and Walters (1986) technique but sections were not 
calcified. Control sections were incubated without substrate or 
without tartaric acid. Twenty MNGC from each of the samples were 
evaluated. The level or intensity of the TRAP reaction product in 
rnultinucleated giant cells located along the bone surface was analyzed 
using the computerized imaging system, Princeton Gamma Tech (PGT) 
lmagecraft System 4+ run on a Digital Equipment Systems PDP 11/73, and 
PGT lmagecraft software (Figure 1). The technique is described in 
detail in Chapter III. Comparisons of the average number of cells 
expressing high TRAP activity were made among the three implant types 
and the tibia. Multiple linear comparisons among the implant groups 
and tibiae were performed using the Welch's t'W test for multiple 
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linear comparisons (Wilcox, 1987). 
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RESULTS 
Active osteoclasts from the proximal tibia were identified as 
multinucleated cells exhibiting vacuolization of the cytoplasm and a 
striated border adjacent to the bone surface (Fig. 2a). At the ultra-
structural level, osteoclasts were identified by ruffled borders limit-
ed by an organelle free, clear zone and a highly vacuolated area adja-
cent to the ruffled border (Figure 2b). Tartrate resitant acid phos-
phatase reaction product was observed as red granules within the cells 
and extracellular staining of the bone matrix adjacent to the osteo-
clasts (Figure 2c). All osteoclasts consistently exhibited the highest 
TRAP staining intensity. 
Each implant was surrounded by a fibrous connective tissue cap-
sule. At the site of the mineralized implant, large multinucleated 
cells were found in contact with the bone particles. Some cells exhib-
ited vacuolization at the bone surface, but most cell-bone contacts 
were unremarkable (Figure 3a,b). The cell membrane adhered to the 
particle surface and often extended processes into the irregularities 
on the surface. The non-bone apposing surface of the cells exhibited 
cytoplasmic folds, often quite elaborate. The nuclei were present most 
often in a linear arrangement, at a random distance from the bone-
apposed cell surface. The majority of the multinucleated cells in con-
tact with the bone particles expressed either a low level of TRAP 
reaction product or absence of the enzyme (Figure 3c). The number of 
MNGCs from the mineralized implants expressing high level of enzyme 
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expression was significantly different from the osteoclasts from the 
tibia and demineralized implants and MNGCs from the composite implants 
(p<O.OS) (Figure 4). 
Large multinucleated cells were present at the osteogenic site 
of the demineralized bone particle implant. The osteogenic site or 
area of mineral deposition was determined using the von Kossa technique 
and only the MNGCs at that site were analyzed. The cells were not as 
large as those seen in the mineralized implant and did not surround the 
bone particles but were present at discrete sites on the newly miner-
alized bone surface (Figure Sa). The ultrastructure of the cell mem-
brane in contact with the particle exhibited extensive infoldings bound 
by smooth organelle-free areas (Figure Sb). Adjacent to the membrane 
infoldings was an area of vacuolization. Rough endoplasmic reticulum 
and mitochondria were the most abundant organelles. These cells were 
similar to the osteoclasts of the proximal tibiae in both morphology 
and TRAP expression (Figure 4, Sb). Almost all MNGCs expressed high 
levels of TRAP reaction product intracellularly. Weak extracellular 
staining was noticed in areas of adjacent bone also had extracellular 
TRAP staining. 
The composite implant recruited a population of multinucleated 
cells similar in size, morphology and expression of TRAP reaction 
product to those recruited to the mineralized implant. These large 
multinucleated cells were found in contact with the mineralized 
particles (Figure 6a). A small population of the MNGCs demonstrated 
clear zones and infoldings of the cytoplasm along the bone-appo~ed 
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surface (Figure 6b). A population of cells which expressed heavy 
amounts of TRAP reaction product was also present along the mineralized 
particles (Figure 6c). These cells were located in discrete areas 
within the implant site, and concentrated the enzyme in the area of the 
cell adjacent to the bone. These cells were not as large and had fewer 
nuclei, compared to the majority of MNGCs exhibiting low levels of TRAP 
reaction product. Ultrastructural examination revealed the majority of 
MNGCs made contacts with the mineralized matrix particles but showed no 
membrane specializations except occasional clear zones or vacuoliza~ 
tion. The majority of cells exhibited moderate to no TRAP reactivity 
with a small subpopulation exhibiting high levels of reaction product 
(Figure 4). The number of cells exhibiting a high level of TRAP 
expression was significantly different from the number of MNGCs from 
the mineralized, demineralized or tibial osteoclasts, (p<0.05). The 
lack of osteoblasts and the lack of patchy von Kassa staining, which is 
characteristic of newly mineralized bone, indicated osteogenesis had 
not occurred. 
62 
DISCUSSION 
Tartrate resistant acid phosphatase and the specific morpholog-
ical features associated with bone resorption allow for the character-
ization and discrimination of the osteoclast from the remaining popula-
tion of bone cells responsible for matrix deposition and maintenance 
and cells of the mononuclear phagocyte system, specifically the macro-
phage polykaryon which exhibits some similar morphological features. 
In the present study, these two parameters, TRAP activity and morphol-
ogy, were used to evaluate cells generated at the sites of subcutan-
eously implanted bone matrix. The osteoclasts from the proximal tibiae 
exhibited ruffled borders and clear zones in contact with the bone sur-
faces and were consistantly heavily stained with TRAP reaction product. 
TRAP has been isolated from bone (Andersson et al., 1984, 1986; Ander-
son and Toverud 1979; 1982) and is generally accepted as a cytochemical 
characteristic of the osteoclast (Minkin, 1972; Hammerstrom et al., 
1971; 1983) and its mononuclear precursors (Baron et al., 1986; van de 
Wijngaert and Burger, 1986). The remaining populations of bone cells, 
mononuclear phagocytes and virtually all other cells except erythro-
cytes express primarily, the tartrate sensitive form of acid phospha-
tase. Recent studies have shown that rat osteoblasts and osteocytes at 
or near the growth plate express low levels of punctate cytoplasmic 
TRAP reactivity (Bianco et al., 1988; Cole and Walters, 1987). Limited 
expression of the enzyme by these cells and the sensitivity to tartrate 
by other cells in the bone microenvironment allow TRAP to be used as a 
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tool for identification of osteoclasts. In some pathological states, 
other cells can express TRAP. Bianco et al. (1987) reported that in 
disease states where macrophage hypersensitivity is expected like, 
chronic granulocyte leukemia and metastasis of carcinoma in the bone 
marrow, a large proportion of bone marrow macrophages express TRAP 
activity. Bianco et al. suggested the expression of the enzyme may be 
due to immunologically mediated activation and that TRAP expression in 
cells of the mononuclear phagocyte system may be a marker of cell 
activation. In an in vitro study, Razdun et al. (1983) reported stimu-
lated monocytes exhibited TRAP activity and concluded that expression 
of TRAP activity may indicate macrophage differentiation. In this 
investigation, the ability of the MNGCs to express low levels of TRAP 
activity may reflect a stimulated or activated state as in the above 
cited studies. 
The number of MNGCs that express a level of TRAP activity and 
morphology similar to that of osteoclasts increased with an increase in 
the amount of demineralized matrix in the subcutaneous bone implant. 
The mineralized implant generated MNGCs that expressed weak TRAP activ-
ity and no ruffled border-a response similar to a chronic inflammatory 
response. A chronic stimulus results in an infiltration of mononuclear 
phagocytes which differentiate into epitheloid cells and fuse to form 
MNGCs (Adams et al., 1976). At 14 days the particles were surrounded 
by mononuclear and MNGCs which have been shown to be osteolytic or less 
specifically, able to digest foreign substances including mineralized 
matrix (Walters and Schneider, 1985; Glowacki, 1982). This indicates 
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the implantation of mineralized matrix does not create an osteolytic 
response that is mediated by osteoclasts but does create an inflamma-
tory response that is osteolytic. Popoff and Marks (1986) supported 
this conclusion and reported implant generated MNGCs were morpholog-
ically distinct from osteoclasts. Walters and Schneider (1988), 
implanting chips of mineralized bone, reported 52% of bone induced MNGC 
were mildly TRAP positive and differed considerably from that observed 
in osteoclasts. 
Glowacki and Cox (1986) however, reported MNGCs surrounding 
mineralized bone particles stained for TRAP activity and expressed 
osteoclast morphology. In the initial qualitative study, MNGCs with 
osteoclastic morphology and TRAP reactivity were described. The level 
of TRAP activity in comparison to active osteoclasts or MNGCs was not 
described. In a subsequent study (Glowacki, 1988), the MNGCs surround-
ing mineralized bone particles from composite implants of bone and 
polyethylene or polymethylmethacrylate were quantitated for levels of 
TRAP activity and shown to stain strongly or very strongly compared to 
MNGCs adjacent to plastic particles but again they were not compared to 
in situ osteoclasts. Our work does not support these findings. Acid 
phosphatase and enzymes in general, may be altered by tissue processing 
(Burstone, 1958). The use of 2.5% glutaraldehyde in this study instead 
of 2.0% paraformaldehyde used in the Glowacki studies, may have de-
creased the intensity of the enzyme reaction product. However, when 
compared to tibial osteoclasts fixed in the same manner, the relative 
difference remains and the MNGCs from the mineralized implant still 
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demonstrate a lower level of activity. 
The osteoclast is a highly specific cell which has been shown to 
be under strict control of a variety of cytokines and hormones, both 
directly and indirectly. The substrate, mineralized bone, and mechan-
ism of action are specialized. Although the mononuclear phagocyte and 
its derivatives have osteolytic capabilities among its repetoire, the 
osteoclast does not share in a wide range of capabilities of the macro-
phage. Implantation of mineralized bone presents the required sub-
strate for osteoclasts but indicates by their absence, that all 
requirements for the generation of osteoclasts have not been met. 
Implantation of demineralized bone served as a control for 
generation of osteoclasts at an ectopic site since implantation of 
demineralized bone matrix initiates a highly reproducible sequence of 
events that leads to bone formation and subsequent remodelling by 
osteoclasts (Reddi and Huggins, 1972). In this investigation, deminer-
alized bone matrix was subcutaneously implanted and at 14 days, the 
majority of MNGCs expressed intense reaction product and osteoclast 
morphology. In the demineralized implant, osteoclasts are present at 
an ectopic site, but only where osteogenesis had been initiated. 
Recruitment of osteoclasts seems to be dependent on (1) the early 
stages of chemotaxis, chondogenesis and osteogenesis and (2) formation 
of a mineralized matrix. Burger et al (1984) co-cultured bone marrow 
mononuclear phagocytes with live mineralized, periosteum and osteo-
clast-free fetal bone rudiments and reported that the activity of 
skeletal cells was a prerequisite for osteoclast recruitment. .Rodan 
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and Martin (1981) also suggested that osteoblasts may be mediators of 
osteoclast activity and need to be present. Implantation of deminer-
alized bone has most frequently been used to study the initial phases 
of osteogenesis however it can also be used to study recruitment of the 
osteoclasts and the initial phases of bone remodelling. 
Approximately 2/3 of the MNGCs elicited from the mixed implant 
exhibited moderate to no TRAP reactivity and macrophage-derived MNGC 
morphology, which was similar to the population profile from the 
mineralized implant. However, the remaining 1/3 of the total MNGCs 
population sampled, exhibited high levels of enzyme reactivity and 
osteoclast-like features. Osteogenesis was not occurring as in the 
demineralized implant. Reddi and Huggins (1972) first reported the 
inability of a mixed sample of demineralized bone and bone ash to 
induce osteogenesis. They reported the presence of osteoclastic giant 
cells which had blocked the transformation of fibroblasts and subse-
quent bone formation. This cell response from the composite implant is 
similar to the mineralized implant but the subpopulation of MNGCs that 
resemble osteoclasts makes it unique. The most obvious reason for the 
unique response is the presence of the demineralized bone matrix. 
Although osteogenesis was not occurring, the presence of demineralized 
bone may have had an impact either directly on osteoclast recruitment 
or indirectly by affecting cells at the site which stimulate recruit-
ment or expression of the osteoclast phenotype. The mineralized matrix 
may impair the full expression and matrix producing function of the 
differentiating progenitor cell although, these cells still may be able 
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to provide the appropriate signals for osteoclast precursor recruitment 
and differentiation. The highly TRAP positive cells were not distrib-
uted uniformly throughout the implant but were present in discrete 
areas which may indicate a localized response within different parts of 
the implant. The osteoclast-like cells were most often found adjacent 
to the mineralized particles which indicates a preference for a miner-
alized substrate. If the response to stimulate osteoclast-like cells 
can be augmented in the mixed implant, or if the recruitment and/ or 
expression of the osteoclast phenotype could be stimulated in the 
mineralized implant, these may be feasible in vivo models for the study 
of osteoclast function at a nonskeletal site. 
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Figure 1. 
Color enhanced digitized image composite of 4 MNGCs (arrows) 
adjacent to bone (b), representing the 4 levels of TRAP reaction 
product intensity (a, no reaction product; b, low intensity; c, 
moderate intensity; d, high intensity). 
Figure 2. 
a. Scattered multinucleated osteoclasts (arrows) from rat 
proximal tibia, present along the trabeculae of bone (b). 
x413 
b. Electron micrograph of multinucleated osteoclast surrounding 
bone (b). Hallmark morphological features of ruffled border 
(arrows) and clear zone (arrow heads) are demonstrated. Note 
smooth appearence of bone surface associated with clear zone 
(area of attachment) and rough appearance of bone surface 
under ruffled border (area of resorption). x3719 
c. Osteoclasts (arrows) from rat proximal tibia containing high 
concentrations of TRAP reaction product. (bone,b) x400 
69 
.. 
t:-
... 
, ~ >t 
·-· -
o!. .. .. 
.t 
., 
2c ' . ,. • 
... 
70 
Figure 3. 
MNGCs elicited by the mineralized bone implant, 2 wks. 
post-implantation: 
a. MNGCs (arrows) surrounding mineralized bone particles (b). 
x272 
b. Stained for TRAP reactivity, MNGCs (arrows) in contact with 
the bone surface (b) exhibit mild reaction product. x425 
c. Electron micrograph of MNGC in contact with a mineralized 
surface. x7500 
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Figure 4. 
TRAP expression in MNGCs elicited by mineralized, demineralized 
and composite bone matrix implants (2 wks. post-implantation) and 
situ osteoclasts. TRAP reactivity scored as high level(++), 
moderate level (+) or absence (0) of reaction product. (mean ±SEM) 
a. mineralized (++) significantly different than tibia 
(++), p<0.05. 
b. mineralized (++) significantly different than 
demineralized (++), (p<0.05. 
c. mineralized (++) significantly different than composite 
(++), p<0.05. 
d. demineralized (++) significantly different than 
composite (++), p<0.05. 
e. composite (++) significantly different than tibia (++), 
p<0.05. 
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Figure 5. 
Osteogenic response elicited by implantation of demineralized bone 
matrix, 2 wks. post-implantation: 
a. Active multinucleated osteoclasts contacting newly 
mineralized bone matrix (b). x640 
b. Electron micrograph of osteoclast exhibiting a ruffled 
border (rb), in contact with the bone surface (b). x6000 
c. Osteoclasts stained intensely with granular TRAP reaction 
product. (bone,b) x413 
7'5 
b 
: ~-
' 
.. ,, 
• 
76 
Figure 6. 
MNGCs elicited by a composite implant, 2 wks. post-implantation: 
a. MNGCs (arrows) surrounding bone particles (b). x272 
b. MNGC in contact with bone particles (b) demonstrating 
membrane specialization at areas of contact. Cell-bone 
contact is unlike that seen in Fig. 3b. x6000 
c. MNGCs (arrows) in contact with bone particles (b), stained for 
TRAP reactivity. Note the range of TRAP reaction product 
concentrations in MNGCs. x264 
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CHAPTER V 
THE EFFECTS OF INTERLEUKIN 2 INFUSION 
ON CELLS ELICITED BY ECTOPIC BONE IMPLANTS 
ABSTRACT 
Investigations into the effects of interleukin 2 (IL-2) on bone 
cell functions are limited. Based on the hypothesis of immune-bone cell 
interactions, the ability of IL-2 to stimulate bone resorption has been 
tested in vitro and the results are conflicting (Gowen and Mundy, 1986; 
Ries et al., 1989). In an attempt to further analyze the effects of 
IL-2 on bone cell function, human rIL-2 (3 x 104 U/day) was infused at 
the site of 3 types of subcutaneous bone implants (mineralized, demin-
eralized and a composite mixture of both types). Implantation of 
pulverized mineralized bone matrix elicits an inflammatory response 
while a demineralized bone implant elicits an osteogenic response and a 
composite implant elicits an inflammatory response with a minor popula-
tion of cells exhibiting osteoclastic characteristics. Tartrate 
resistant acid phosphatase (TRAP) and ultrastructural analyses were 
used as criteria to assess whether IL-2 could stimulate differentiation 
of these cells at the site into osteoclasts or modulate the cells at 
the site of the implants to express the osteoclast phenotype. Multinu-
cleated cells elicited by the IL-2 treated mineralized implants exhib-
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ited weak TRAP activity and no osteoclastic features. There was no 
change in the multinucleated cells elicited by the IL-2 treated miner-
alized implants compared to control. Osteoclasts from the treated and 
control demineralized implants demonstrated high levels of TRAP activ-
ity and osteoclastic morphology. The osteogenic response seemed to be 
enhanced by IL-2. An increase in the number of highly TRAP positive 
multinucleated cells and cells exhibiting clear zones and ruffled bor-
ders was present in the IL-2 treated composite implants versus con-
trols, however the increases were not significant. From these implant 
studies, it has been shown that IL-2 has no effect on the inflammatory 
multinucleated cells elicited by the mineralized implant and it was 
unable to promote osteoclast differentiation or expression. In the 
demineralized, IL-2 may have an effect on bone cell function recognized 
by an enhancement of the osteogenic response. IL-2, like other 
cytokines, may have a profound direct or indirect effect on bone cell 
function. 
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INTRODUCTION 
Cytokines, as local mediators of bone cell function, have 
recently been shown to play an integral role in the complex functions 
of bone formation, growth, remodelling and repair in health and dis-
ease. One means by which the relationship between the immune and skele-
tal systems has been recognized is through the study of osteopetrosis, 
a congenital disease resulting in accumulation of bone matrix. Func-
tional defects in both immune cells and osteoclasts have been shown 
which may be the result of a common defect in development since immune 
cells and osteoclasts are of hemopoietic origin. Transplantation of 
bone marrow or splenocytes has been shown to cure the disease in some 
mutant rodents (Walker 1975; Ash et al., 1980; Schneider 1985). Anoth-
er aspect of the relationship between the immune system and the skele-
tal system is the modulatory effects of immune cell products on bone 
cell function. An effect was first recognized when products of mitogen-
activated peripheral blood mononuclear cells stimulated bone resorption 
by increasing the number and function of osteoclasts in bone organ 
cultures (Horton et al., 1972). Osteoclast activating factor, as it 
was first described, has now been characterized as a family of cyto-
kines including interleukin-1 (IL-1) and tumor necrosis factors (TNF a) 
and (TNFS ). These stimulators of bone resorption may function in both 
health and disease. In chronic inflammatory diseases such as rheuma-
toid arthritis and periodontitis, the infiltrating immune cells release 
products that may contribute to osteolysis and tissue destruction. 
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Analysis of joint fluid taken from patients with rheumatoid arthritis 
indicate the presence of osteoclast activating factors (Nouri et al., 
1984b; DiGiovani et al., 1988; Saxne et al., 1988). 
Cyclosporin A is a potent immunosuppressive agent that is 
frequently used to control graft rejection after organ transplant sur-
gery. Among a number of effects, it has been shown to inhibit T-cell 
proliferation and activation, B-cell differentiation, and secretion of 
cytokines (specifically IL-1 and IL-2) (Thomson et al., 1984; Bunjes et 
al., 1981). Cyclosporin has also been shown to inhibit normal bone 
resorption in vivo (Orcel et al., 1989) and parathyroid hormone, 
prostaglandin E2 , 1,25-dihyroxyvitamin o3 and osteoclast activating 
factor induced resorption of fetal rat limb bones in vitro (Stewart et 
al., 1986; 1989). It seems possible that the inhibitory effects on 
bone resorption may be an indirect effect of suppressed immune cell 
activity. Normal bone cell function may be dependent on normal immune 
system function. 
The effects of isolated cytokines on bone have been evaluated in 
vitro and have been shown to have a variety of effects. The conclu-
conclusions from these investigations however, may not address the 
complex interactions and profound indirect effects of cytokines, the 
immune cells that produce them, systemic hormones and bone cell func-
tion. Interleukin 2 (IL-2) is one such cytokine that may have a com-
plex indirect mechanism of action. IL-2 was first functionally des-
cribed as thymocyte stimulating factor due to its ability to enhance 
the thymocyte mitogenic response to phycohemagglutinin and concanavalin 
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A (Morgan et al., 1976). It is also able to regulate the production of 
cytokines (Numerof et al., 1988; Nedwin et al., 1985), play a role in 
wound healing (Barbul et al., 1986) and act as an antineoplastic agent 
in cancer therapy (Rosenberg et al., 1985; Lotze et al., 1986). IL-2 
therapy produces toxic side effects including fever, hypotension, in-
creased plasma acute-phase proteins and increased stress-related pitu-
itary hormones (Mier et al., 1988; Mier et al., 1987). 
Investigations into the effects of IL-2 on the skeleton are 
limited. Based on the premise that other immune cell products may 
contribute to osteoclast activating factor activity, Gowen and Mundy 
(1986) tested IL-1, IL-2 and interferon-y for their activity in the 
mouse calvarial resorption assay. IL-2 failed to stimulate bone 
resorption. In a similar study by Ries et al. (1989), IL-2 was shown 
to stimulate osteoclastic activity by increasing acid production and 
45 1 . 1 ca cium re ease. Other studies have focused on the role of IL-2 in 
the connective tissue destruction of chronic inflammatory conditions, 
including rheumatoid arthritis. Elevated levels of IL-1 and IL-2 in 
the joint fliud of patients with rheumatoid arthritis have been re-
ported (Nouri et al., 1984a; Nouri et al., 1984b). The effects of this 
cytokine on bone cell function or its mechanism of action, whether 
direct or indirect, are unknown. IL-2 does seem to indicate another 
link between the immune and skeletal systems. 
A system that may evaluate the effects of IL-2 in vivo is the 
subcutaneous bone matrix implant model. Implantation of pulverized 
mineralized matrix produces a chronic inflammatory response that is 
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osteolytic but not osteoclastic. Using the presence of tartrate 
resistant acid phosphatase (TRAP) and ultrastructural morphology of the 
osteoclast as criteria, the ability of IL-2 to stimulate the differ-
entiation of osteoclasts at this ectopic site can be evaluated. 
Implantation of a demineralized matrix produces an osteogenic response. 
The effects of IL-2 on the promotion of an osteogenic site and subse-
quent osteoclastic activity can be evaluated using this demineralized 
matrix implant. A composite of both mineralized and demineralized bone 
matrix has been shown to generate a large population of non-osteo-
clastic multinucleated giant cells and a small population of osteo-
clast-like cells. The effects of IL-2 on these populations will be 
evaluated. 
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MATERIAL AND METHODS 
~imals 
These studies were performed using Norway-hooded Long Evans rats 
(Harlan Labs, IN). All animals were maintained and used according to 
the recornrnedations in the Guide for the care and use of Laboratory Ani-
mals and the Guidelines of the Institutional Animal Care and Use 
Committee at Loyola University Medical Center. 
Bone Powder Preparation 
Mineralized bone implant: Tibiae and fibulae were removed from 4-8 wk 
old Norway-hooded Long Evans rats. The soft tissue and cartilagenous 
epiphyses were removed and the marrow cavities were flushed with dis-
tilled water. The cleaned diaphyses were washed overnight in distilled 
water then extracted with absolute ethanol (30 min) and anhydrous ether 
(30 min). The bones were dried, pulverized with a mortar and pestle 
and sieved to yield particles 75-250 um in diameter. Sterile water was 
added to samples to create cohesive pellets of bone particles that 
could be easily implanted subcutaneously. The pellets were air dried 
and sterilized by ultraviolet (U.V.) radiation. 
Demineralized bone implant: The mineralized bone particles prepared 
above were treated with 0.5 N HCl, 25 meq/gm (demineralizing agent) for 
3 hrs followed by repeated washings of cold deionized water to 
thoroughly remove the acid, absolute ethanol (30 min) and anhydrous 
ether (30 min). Sterile water was added to samples of demineralized 
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bone to create pellets. The pellets were air dried and sterilized by 
u.V. radiation. 
Composite implant: A composite bone particle implant was prepared from 
25 mg mineralized bone powder and 5 mg demineralized bone powder. Ster-
ile water was added to the bone particle mixture to create cohesive 
pellets which were air dried and sterilized by U.V. radiation. 
IL-2 Administration 
Human rIL-2 was administered by constant infusion at a dose of 3 
4 
x 10 U/day for 14 days (Piquet et al., 1986). Infusion of rIL-2 at the 
site of the bone implants was acheived by subcutaneous implantion of 
the Alzet osmotic minipump (Alzet Corp., Palo Alto, CA; model 2002) at 
the site. Human rIL-2 was kindly provided by Hoffmann-LaRoche, Nutley, 
N.J. rIL-2 and was diluted in 0.9% NaCl, 5.0 mg/ml mannitol and 75 mg/l 
ml SDS; the control rats received pumps loaded with vehicle only. 
Implants 
Five wk old male Norway-hooded Long Evans rats were anesthe-
tized with chloral hydrate (400 mg/kg). Dorsal, upper thoracic inci-
sions were made bilaterally and subcutaneous pockets were created. One 
pocket was extended anteriorly and medially. The bone powder pellets 
were placed in the subcutaneous pockets, one pellet placed as far 
anteriorly as possible, in the cervical region; the remaining two pel-
lets were placed in the left and right scapular regions. Each animal 
received one of each of the three types of bone implants. A third 
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midline, lower thoracic incision was made in each animal and a subcuta-
neous pocket was created anteriorly. An Alzet minipump was inserted 
into the pocket, with the delivery outlet in the vicinity of the three 
bone implants thus concentrating the cytokine at the site of the bone 
implants. The incisions were sutured and treated with betadine. Two 
wks post-implantation, the animals were sacrificed via ether inhala-
tion, and the implants and proximal tibia were carefully excised. The 
minipumps were removed and analyzed for proper delivery. 
Morphological and Histochemical Analyses 
One third of the specimens and a sample of proximal tibia were 
immediately fixed in 2.5% glutaraldehyde, 0.1 M cacodylate buffer (p.H. 
7.2) for 48 hrs., post-fixed in 1% osmium tetroxide, dehydrated in 
ascending concentrations of ethanol, and embedded in Epon 812. One 
micron sections were cut and stained with toluidine blue and evaluated 
by light microscopy. Thin sections (60-70nm) were cut and stained with 
uranyl acetate and lead citrate for ultrastructural analysis using the 
Hitachi H600 electron microscope. 
Another third of each specimen and samples of proximal tibia 
were immediately fixed in cold 1% paraformaldehyde, 0.1 M cacodylate 
buffer (pH 7.2) with 7% sucrose for 3 hrs, dehydrated in ascending 
concentrations of cold acetone and embedded in JB-4. Three micron 
sections were cut and allowed to adhere to gel-coated slides in the 
cold for 5 days. The sections were then stained for alkaline phospha-
tase. Alkaline phosphatase was demonstrated using Burstone's complete 
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media (Pearse, 1968) containing Napthol AS-BI phosphate as a substrate 
and Red-violet LB diazonium salt as the capture agent in 0.1 M Trizma 
buffer,(pH 8.5). The substrate was omitted from control media. 
The remaining third of each specimen and samples of proximal 
tibiae were stain for tartrate resistant acid phosphatase activity 
using 50 mM L(+)-tartaric acid, and a modified Cole and Walters (1986) 
technique (samples were not decalcified), or for mineral content using 
the von Kossa technique. Control sections were incubated without sub-
strate. The level or intensity of the TRAP reaction product in multinu-
cleated giant cells located along the bone surface was assessed using 
the PGT System 4+ image processor, DEC PDP 11-73, and PGT Imagecraft 
software. The cells were catagorized into 3 groups according to the 
level of TRAP expression. All tibial osteoclasts exhibit a high to 
moderate level of reaction product (+++ or ++) and these ranges were 
combined. The IL-2 treated cell population profiles were compared to 
the controls for each of the three implant types and the tibiae. 
Comparisons of the number of cells expressing high levels of TRAP reac-
tion product were also made among the implant groups and the tibiae. 
Multiple linear comparisons among the three implant groups and tibial 
osteoclasts were performed using the Dunn-Bonferroni t-test and the 
Welch's t'W test for multiple linear comparisons (Wilcox, 1987). 
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RESULTS 
Active osteoclasts from the proximal tibia in both IL-2 treated 
and controls were identified as multinucleated cells exhibiting vacuol-
ization of the cytoplasm adjacent to the bone surface. Tartrate 
resistant acid phosphatase reaction product was observed as red gran-
ules within the cells and extracellular staining of the bone matrix 
adjacent to the osteoclasts. All osteoclasts consistently exhibited 
the highest staining intensity. At the ultrastructural level, osteo-
clasts were identified as multinucleated cells with ruffled borders 
limited by an organelle free, clear zone along the bone surface and a 
highly vacuolated area adjacent to the ruffled border. 
Each implant was surrounded by a fibrous connective tissue 
capsule. At the site of the mineralized implant, large multinucleated 
cells were found in contact with the bone particles. Von Kassa stain-
ing indicated the particles were mineralized. Some cells exhibited 
vacuolization of the membrane at the bone surface, but most cell-bone 
contacts were unremarkable (Figure la). The cell membrane adhered to 
the particle surface and often extended processes into the irregular-
ities on the surface. The non-bone apposing surface of the cells 
exhibited cytoplasmic folds, often quite elaborate. The majority of 
the rnultinucleated cells in contact with the bone particles expressed 
either a low level of TRAP reaction product or absence of the enzyme 
(Figure lb). Other MNGCs that were present at the site and not in 
contact with bone particles also expressed low levels of TRAP. These 
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cells were not quantitated. No cells were stained with alkaline phos-
phatase. The enzyme expression in the population of MNGCs analyzed was 
significantly lower than the osteoclasts (p<.05) but there was no 
difference in control mineralized implant versus IL-2 treated mineral-
ized implant (Figure 2). 
Large multinucleated cells were present at the osteogenic site 
of the demineralized bone particle implant. The osteogenic site or 
area of mineral depositon was determined using the von Kossa technique 
and by the presence of alkaline phosphatase containing cells. Only the 
MNGCs in that site were analyzed. The cells were not as large as those 
seen in the mineralized implant and did not surround the bone particles 
but were present at discrete sites on the newly mineralized bone sur-
face. The ultrastructure of the cell membrane in contact with the 
particle exhibited extensive infoldings bound by smooth organelle-free 
areas (Figure 3a). Adjacent to the membrane infoldings was an area of 
vacuolization. Rough endoplasmic reticulum and mitochondria were the 
most abundant organelles. These cells were morphologically similar to 
the osteoclasts of the proximal tibiae. In these areas of the implant 
almost all MNGCs expressed high levels of TRAP reaction product intra-
cellularly (Figure 3b). The TRAP expression in the MNGCs from the IL-2 
treated and control demineralized implants and tibial osteoclasts was 
not significantly different. 
The composite implant recruited a population of multinucleated 
cells similar in size, morphology and expression of TRAP reaction 
product to those recruited to the mineralized implant except for a 
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subpopulation of cells exhibiting osteoclastic features (Figure 4a). 
The majority of cells exhibited moderate to no TRAP reactivity with a 
subpopulation exhibiting high levels of reaction product (Figure 2). 
These cells were present on the surface of the bone particles and were 
not as large and had fewer nuclei, than the majority of MNGCs exhib-
iting low levels of TRAP reaction product (Figure 4b). Image analysis 
revealed nonspecific extracellular staining and TRAP concentrated along 
the bone-apposed cell surface. Statistical analysis did not reveal a 
significant difference between TRAP expression in the IL-2 treated ver-
sus control composite implant however a shift in TRAP expression was 
evident. Von Kassa and alkaline phosphatase staining revealed no evi-
dence of osteogenesis at these implant sites. 
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DISCUSSION 
The role of IL-2 in these models for osteolysis and osteogenesis 
is uncertain. The data indicates osteoclasts were not recruited by 
infusion of IL-2 at the implantation site of mineralized bone parti-
cles, based on the lack of TRAP expression and osteoclast morphology. 
The response to implantation of mineralized bone particles can be 
characterized as a chronic inflammatory response. Initially lympho-
cytes and monocytes are recruited to the site. The monocytes, macro-
phages and multinucleated giant cells surround the particles and 
attempt to degrade them while fibroblasts attempt to isolate the 
irritant by proliferating and producing a fibrous capsule. Lymphocytes 
are present during these events and their role which may be signifi-
cant, is not well defined. Lymphocytes may act as modulators of macro-
phage and fibroblast activity. Cytokines, like IL-2, which have a 
stimulatory effect on lymphocytes may therefore have an indirect role 
in the inflammatory response. 
Wound healing, which may be the endpoint of an inflammatory re-
sponse, has been shown to be significantly augmented by chronic IL-2 
administration (Barbul et al., 1986). One mechanism of action proposed 
by the authors is that IL-2 stimulated lymphocytes to release factors 
which promote macrophages to produce IL-1. In this case, IL-1 may 
stimulate fibroblastogenesis but in the case of the mineralized bone 
implant, it may also stimulate osteolysis. At 14 day post-implanta-
tion, the osteoclasts from the demineralized implant expressed high 
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levels of TRAP reaction product. There was no significant difference 
between the TRAP expressed by the osteoclasts from the experimental and 
control demineralized implants indicating that IL-2 did not inhibit the 
recruitment or activity of osteoclasts during demineralized matrix in-
duced bone formation. By 14 days after implantation, the development 
of a marrow cavity has begun. As in normal bone development, bone 
cells are in close proximity to the bone marrow cells and specialized 
environment. Infusion of IL-2 may have an effect on the developing 
hemopoietic cells. Chronic administration of IL-2 to osteopetrotic 
mutant rats has produced both changes in natural killer cell activity 
and bone resorption (Schneider et al., 1988, 1990). 
Enhanced bone formation was observed in two samples. Recently a 
study has shown the mitogenic activity of IL-1 for fibroblasts appears 
to be indirect and mediated by the platelet derived growth factor 
(PDGF)-A chain gene which has a paracrine or autocrine effect (Raines 
et al., 1989). PDGF is member of the growth factor family that is 
responsible for regulating the proliferation of connective tissue 
cells. PDGF has been shown to enhance induction of bone formation by 
demineralized bone matrix implants (Howes et al., 1988). Since IL-2 
can stimulate the production of IL-1, the accelerated osteogenesis may 
be due to IL-1 stimulated PDGF production. In patients with intra-
abdorninal cancers, IL-2 may be administered directly into the abdominal 
cavity by Technokoff catheter. A side effect of intraabdominal 
administration lyrnphokine activated killer (LAK)/IL-2 therapy is 
fibrosis. The fibrosis may be due to cytokines produced by the LAK 
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cells or the induction of cytokines produced by host cells stimulated 
by IL-2. Wound healing factors like TGF-S and PDGF, which may be pro-
duced, could create the fibrosing response which may be similar to the 
enhancement of the osteogenic response in the demineralized implant 
(Urba et al., 1989). 
The composite implant showed a subpopulation with osteoclast-
like TRAP expression and morphology whose number increased with IL-2 
administration. From the demineralized bone implant, it was shown that 
IL-2 did not inhibit recruitment or osteoclast activity. IL-2 promoted 
osteoclast-like TRAP expression and the morphological features of the 
multinucleated giant cells from the mixed implant. I was unable to 
determine if the effect was direct or via the production of other cyto-
kines. I was also unable to determine from this study if the increase 
in the number of cells expressing high levels of TRAP reaction product 
and osteoclast-like morphology was due to promoting osteoclast pheno-
type in cells that had not expressed it previously by recruiting new 
cells to the implant site. Further studies are needed to address the 
specific effects of IL-2 on osteoclast function and/or development. 
The effects of IL-2 on this chronic inflammatory response was 
not evaluated in this investigation but may be significant. Cells 
extracted from inflamed periodontal lesions are capable of producing 
both IL-2 vitro as assessed by the method of Warren and Pembrey 
(1981), and bone resorbing factors, as assessed by calcium release from 
cultured mouse calvariae (Seymour et al., 1985). IL-2 has also been 
detected in the synovial fluid of patients with rheumatoid arthritis, 
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alkylosing spondolysis and psoratiac arthritis, irnmunoinflarnmatory 
diseases and osteoarthritis, a degenerative disease (Nouri et al., 
1984a). The presence of IL-2 in the synovial fluid of patients with 
immunoinflarnmatory disease is not surprising because activated lympho-
cytes which produce IL-2 are present. However, the presence of IL-2 in 
the joint fluid of osteoarthritics is surprising because few activated 
lymphocytes are present. Regardless of the nature of the disease, 
these finding indicate lymphocytes and IL-2 which facilitates their 
expansion, may contribute to connective tissue degenerative diseases. 
The most relevant effect of IL-2 to this investigation is its 
ability to stimulate the expression of cytokines which may play a role 
in bone remodelling. Human peripheral blood mononuclear cells (PBMCs) 
were induced by recombinant IL-2 to secrete TNF-a and TNF-8 (Nedwin et 
al., 1985). Production of TNF-a and TNF-8 was augmented by combining 
IL-2 with recombinant interferon-y (rlNF-Y). IL-2 has also been shown 
to stimulate the production of IL-la and IL-18 by human PBMCs in 
vitro (Numerof et al., 1988). The results indicated that the 11-1 is 
largely derived from direct stimulation of monocytes. 
Both TNF and 11-1 have been shown to have effects on bone cell 
function. TNF-a stimulates DNA synthesis which resulted in an increase 
number of collagen synthesizing cells, but it has a direct inhibitory 
effect on osteoblast function (Canalis, 1987; Centrella et al., 1988). 
Bertolini et al. (1986) have demonstrated human rTNF-a and rTNF- B 
induced osteoclastic bone resorption in organ cutures of fetal rat 
calvariae. The effects of TNF appear to be mediated by the osteoblast 
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(Thomson et al., 1987). Its ability to stimulate osteoclastic resorp-
tion and its presence in the the synovial fluid from patients with 
rheumatoid arthritis provides evidence that TNF-amay play a signifi-
cant role in connective tissue destruction and more specifically the 
pathogenesis of arthritis (Di Giovine et al., 1988; Saxne et al., 
1988). 
IL-1 has also been shown to affect both bone formation and 
resorption. Using the calvarial resorption assay, IL-1 has been shown 
to stimulate DNA, collagen and noncollagenous protein synthesis but 
exposure to IL-1 at high doses or for long periods of time results in 
inhibition of collagen synthesis (Canalis, 1987). Using the osteo-
blastic cell line MC3T3-El, IL-1 S stimulated cell proliferation but 
inhibited alkaline phosphatase and collagen synthesis (Ikeda et al., 
1988). Both studies imply the importance of IL-1 S in the local 
regulatory mechanism of bone remodelling. The effects of IL-lS on 
bone formation seem to be secondary to its potent effects on bone 
resorption. Gowen and colleagues have shown that highly purified IL-1 
and recombinant IL-1 resorbs bone in vitro (Gowen et al., 1983; Gowen 
and Mundy, 1986). The effect is indirect and mediated by the osteo-
blast (Thomson et al., 1986). It is now thought that IL-1 is major 
constituent of OAF and is 1000 times more potent than TNF (Thomson et 
al., 1986). IL-1 has also been shown to have synergistic effects with 
other cytokines and hormones and its role in physiological and patho-
logical bone loss may be significant (Dewhirst et al., 1987; Lorenzo et 
al., 1988; Tatakis et al., 1988). 
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The use of IL-2 therapy as an antineoplastic agent in cancer 
treatment has proveri effective in some cases. It does however, produce 
toxic side effects. The effects on the skeleton have not been 
investigated. In this investigation, it was shown that IL-2 has an 
effect on the expression of TRAP and osteoclast morphology. The role 
of IL-2 in bone cell function may be a complex one. Further investi-
gation into the role of IL-2, both direct and indirect, and the role of 
immune cells in the mechanisms of bone formation, growth, and remodel-
ling is needed to further understand relationship between the immune 
and skeletal systems. 
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Figure 1. 
Sections of IL-2 treated mineralized bone implant 2 wks. 
post-implantation: 
a. MNGC adjacent to bone particle (b). The MNGC shows no membrane 
specializations at the area of contact with the bone surface. 
x6500 
b. Mild TRAP reactivity in MNGCs (arrows) contacting the bone 
particles (b). x264 
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Figure 2. 
TRAP reactivity in MNGCs elicited from mineralized, demineralized 
and composite bone implants (2 wks. post-implantation) and 
osteoclasts from IL-2 treated (t) and control (c) rats. TRAP 
expression scored as high level(++), moderate level(+), and 
absence (0) of reaction product. (mean ±SEM). 
a. mineralized (T) (++) is significantly different than 
tibia (C) (++) p<0.05. 
b. mineralized (T) (++) is significantly different than 
demineralized (T) (++), p<0.05. 
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Figure 3. 
Sections of IL-2 treated demineralized bone implant: 
a. Multinucleated osteoclast displaying a ruffled border (rb) 
at the bone surface (b). x4875 
b. Osteoclasts (arrows) at the osteogenic site, stained intensely 
with granular TRAP reaction product. (bone,b) x438 
102 
,., 
' 'et 
) 
• 
103 
Figure 4. 
Sections of IL-2 treated composite bone implant: 
a. MNGC adjacent to bone (b) demonstrating clear zone (cz) and 
ruffled border (rb). Note the degraded appearance of the bone 
surface subjacent to the ruffled border area. x6125 
b. MNGCs (arrows) contacting bone particles (b). Note the 
intensity of the intracellular reaction product along the 
area of cell-bone contact. x413 
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CHAPTER VI 
THE EFFECTS OF 1,25 DIHYDROXYVITAMIN D3 , 
PARATHYROID HORMONE AND CALCITONIN 
ON THE CELLS ELICITED BY ECTOPIC BONE IMPLANTS 
ABSTRACT 
The nature of the cells recruited to the site of subcutaneously 
implanted, devitalized bone matrix are dependent on the mineral content 
of the implant. The difference between macrophage derived-multinucle-
ated giant cells (MNGC)s and osteoclasts can be determined on the basis 
of morphological features and level of tartrate resistant acid phospha-
tase (TRAP) expression. Two wks post-implantation, MNGCs are present 
at the site of mineralized bone matrix particles and fail to exhibit 
osteoclast morphology or a high level of TRAP, while MNGCs similar to 
osteoclasts are present at the site of demineralized and composite 
implants. In an attempt to recruit, stimulate differentiation and 
expression of the osteoclast phenotype, or inhibit these effects, 
osteotropic hormones, 1,25 dihydroxyvitamin o3 (l,25(0H) 2D3 ) (2.08 
pmoljhr), parathyroid hormone (PTH) (1.24 U/hr) and calcitonin (CT) 
mU/hr) were infused locally into the area of 3 types of bone matrix 
implants. Control animals received the 3 types of bone implants and 
vehicle. Two wks post-implantation, the implants were removed along 
with proximal tibiae from each animal and processed for histochemical 
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and ultrastructural analyses. The level of TRAP activity in the MNGCs 
from each of the three implants and tibial osteoclasts were assessed 
using an image analyzer. No MNGCs from any treated or control miner-
alized groups expressed high levels of TRAP or membrane specializa-
tions, characteristic of the osteoclast. The l,2S(OH) 2D3-treated 
composite implants had more MNGCs expressing higher levels of TRAP 
activity compared to controls (p<.05). There were no changes in TRAP 
expression in the PTH or CT-treated composite groups. Ultrastruc-
turally, both treated and control composite groups showed MNGCs with 
osteoclastic morphology. In the PTH stimulated demineralized group, the 
demineralized implant was not osteogenic. There was no difference 
between treated and control in the l,25(0H) 2D3 and CT treated deminer-
alized implants. In summary, the hormones did not appear to effect the 
MNGCs elicited by the mineralized implant since they are probably not 
osteoclastic. l,25(0H) 2D3 which is thought to exert its effect on imma-
ture osteoclasts, in contrast to PTH which stimulates mature osteo-
clasts, was effective in increasing the number of MNGCs expressing high 
level of TRAP in the composite implants. PTH completely inhibited the 
osteogenic process in the demineralized treated implant. Because of 
the presence of inflammatory and osteoclast-like cells in the composite 
implant, and its possible cellular modulation by hormones, the 
composite implant may be a valuable model for inflammatory bone loss. 
107 
INTRODUCTION 
Ectopic bone implant systems have been developed to study both 
bone resorption and bone formation using mineralized and demineralized 
bone matrix implants, respectively. Although the response to the 
mineralized bone matrix is osteolytic, there is some discrepancy as to 
whether the cells responsible for bone removal are osteoclasts. 
Glowacki and Cox (1986) claimed osteoclasts, which were identified 
morphologically and histochemically, are present 12 days post-
implantation. Walters and Schneider (1985,1987) and Popoff and Marks 
(1986), however, dispute this claim and describe the multinucleated 
giant cells (MNGCs) as osteolytic but non-osteoclastic, due to lack of 
ruffled borders and low tartrate resistant acid phosphatase (TRAP) 
activity. I substantiate these results in this study and in an earlier 
investigation (Chapter IV). The identity of these MNGCs is critical as 
to whether this mineralized bone implant system can be used as a model 
to study osteoclast function and normal bone remodelling. Whether 
osteoclasts can be found at the site of ectopically implanted 
mineralized bone matrix remains in question. 
The osteogenic response elicited by demineralized bone particles 
is similar to endochondral bone formation, including development of a 
marrow cavity at 21 days post-implantation. Although this model system 
has been extensively used to study bone formation, this type of implant 
can also be used to study bone remodelling. The fact that osteoclasts 
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are recruited to the osteogenic site and are responsible for remodel-
ling the newly mineralized matrix has not been disputed. Functional 
osteoclasts can be elicited at this site however only after the appear-
ance of osteoblasts and the formation of mineralized matrix. The 
osteoclasts present at this implant may be used for comparison to the 
MNGCs elicited at the mineralized site. 
Although not as extensively investigated, implanting a composite 
of mineralized bone matrix and demineralized bone matrix results in the 
appearance of MNGCs and a subpopulation of cells which exhibit osteo-
clastic morphology. This is a unique response since a population of 
cells with osteoclastic characteristics are present without the occur-
rence of osteogenesis as in the demineralized implant. The ability of 
the demineralized matrix to induce bone formation is inhibited, however 
it seems to be able to elicit osteoclast-like cells along with the 
MNGCs that are elicited by the mineralized matrix. 
In this investigation, the relationships between MNGCs and 
osteoclasts, the ability of three types of bone matrix implants to 
elicit specific populations of cells, and the use of these implants as 
models for physiological and/or pathological bone resorption will be 
addressed. Specifically, the MNGCs will be assessed morphologically 
for classic osteoclastic features, and histochemically for expression 
of TRAP, and compared with multinucleated giant cells and tibial osteo-
clasts. TRAP has been proposed as a marker for the osteoclast and its 
precursor and can easily be demonstrated (Minkin, 1982; Cole and 
Walters, 1987). A high level of cytoplasmic TRAP expression and the 
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morphological feature of the ruffled border provide a quick and easy 
method for osteoclast identification and have been extensively used in 
in vitro investigations (Ibbotson et al., 1984; MacDonald et al., 1987; 
--
Roodman et al., 1985). Comparison among the MNGCs elicited by each of 
the three types of bone implants will reveal morphological and histo-
chemical similarities and differences which are important to determine 
which implants can be used for the study of osteoclastic bone resorp-
tion. 
Hormone infusion will be used to further stimulate or inhibit 
the systems to recruit osteoclast precursors and their subsequent 
fusion into functional osteoclasts and/or stimulate the expression of 
the osteoclastic phenotype and function in the cells already present. 
The hormones include parathyroid hormone (PTH) and 1,25 dihydroxy-
vitamin n3 (l,25(0H) 2D3), stimulators of osteoclastic function and 
calcitonin (CT) an inhibitor of osteoclastic function. The ability of 
the cells at the ectopic site to respond to these osteotropic hormones 
will provide another means to assess the true nature of their identity. 
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MATERIALS AND METHODS 
~nimals 
These studies were performed using Norway-hooded Long Evans rats 
(Harlan Labs, IN). All animals were maintained and used according to 
the recommedations in the Guide for the Care and Use of Laboratory 
Animals and the guidelines of the Institutional Animal Care and Use 
Committee at Loyola University Medical Center. 
Bone Implant Preparation 
Mineralized bone implant: Tibiae and fibulae were removed from 4-8 wk 
old Norway-hooded Long Evans rats. The soft tissue and cartilagenous 
epiphyses were removed and the marrow cavities were flushed with dis-
tilled water. The cleaned diaphyses were washed overnight in distilled 
water then extracted with absolute ethanol (30 min) and anhydrous ether 
(30 min). The bones were dried, pulverized with a mortar and pestle 
and sieved to yield particles 75-250 um in diameter. Sterile water was 
added to 50 mg samples to create cohesive pellets of bone particles 
that could easily be implanted subcutaneously. The pellets were air 
dried and sterilized by ultraviolet (U.V.) radiation. 
Demineralized bone implant: The mineralized bone powder prepared above 
was treated with 0.5 N HCl, 25 meq/gm (demineralizing agent) for 3 hrs 
followed by repeated washings of cold deionized water to thoroughly 
remove the acid, absolute ethanol (30 min) and anhydrous ether (30 
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min). Sterile water was added to 10 mg samples of demineralized bone 
to create pellets. The pellets were air dried and sterilized by U.V. 
radiation. 
Composite bone implant: A composite bone powder implant was created 
from 25 mg of mineralized bone matrix and 5 mg of demineralized bone 
matrix. Sterile water was added to the mixture of the two powders to 
create cohesive pellets which were air dried and sterilized by U.V. 
radiation. 
Hormone Administration 
Bovine PTH fragments 1-34 (10,000 U/mg) was purchased from Sigma 
Chemical Co., St. Louis, MO. It was dissolved in a vehicle of 10- 3 HCl 
in 0.9% NaCl containing 20 mg/ml cysteine'HCl (Rasmussen, 1959) and 
delivered at a rate of 1.24 U/hr (Obie and Cooper, 1979) (n=4). 
l,25(0H) 2D3 was a gift from Dr. Uskokovic at Hoffmann LaRoche, Nutley, 
N.J. It was dissolved in a vehicle of propylene glycol and delivered 
at at rate of 2.08 pmol/hr (Parfitt et al., 1984; Brommage et al., 
1983) (n=5). Salmon CT (4500 U/mg) was a gift from Dr. J. Bastian at 
Armour Chemical Co., Kankakee, IL. It was dissolved in a vehicle of 1% 
gelatin, pH adjusted to 3.2 with concentrated HCl and delivered at a 
rate of 42 mU/hr (Bastian et al., 1978) (n=4). Infusion of the hor-
mones at the site of the bone implants was acheived by subcutaneous 
implantation of the Alzet osmotic minipwnp, Model 2002 (Palo Alto, CA) 
at an adjacent site. Control pwnps, containing the appropriate vehi-
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cles, were also prepared for each of the three hormone studies. The 
length of infusion was 14 days. 
!,!?plants 
Five wk old male Norway-hooded Long Evans rats (n=l6) were 
anesthetized with chloral hydrate (400 mg/kg). Dorsal,upper thoracic 
incisions were made bilaterally and subcutaneous pockets were created. 
One pocket was extended anteriorly and medially. The bone powder pel-
lets were placed in the subcutaneous pockets, one pellet placed as far 
anteriorly as possible, in the cervical region; the remaining two pel-
lets were placed in the left and right scapular regions, respectively. 
Each animal received one of each of the three types of bone implants. 
A third midline, lower thoracic incision was made in each animal and a 
subcutaneous pocket was created anteriorly. An Alzet minipump, 
containing one of the hormones or their respective vehicles, was 
inserted into the pocket, with the delivery outlet in the vicinity of 
the three bone implants, concentrating the hormone at the site of the 
bone implants. The incisions were sutured and treated with betadine. 
Two wks post-implantation, the animals were sacrificed via ether inhal-
ation, and the implants and proximal tibiae were carefully excised. 
The minipumps were removed and analyzed for proper delivery. 
Morphological and Histochemical Analyses 
One third of the implant specimens and samples of proximal tibia 
were inunediately fixed in 2.5% glutaraldehyde, 0.1 M cacodylate buffer 
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(pH 7.2) for 48 hrs., post-fixed in 1% osmuim tetroxide, dehydrated in 
ascending concentrations of ethanol, and embedded in Epon 812. One 
micron sections were cut and stained with toluidine blue and evaluated 
by light microscopy. Thin sections (60-70nm) were cut and stained with 
uranyl acetate and lead citrate for ultrastructural analysis, using the 
Hitachi H600 electron microscope. 
Another third of the specimens and samples of proximal tibia 
were prepared for demonstrating alkaline phosphatase activity. Samples 
were immediately fixed in cold 1% paraformaldehyde, 0.1 M cacodylate 
buffer (pH 7.2) with 7% sucrose for 3 hrs, dehydrated in ascending 
concentrations of cold acetone and embedded in JB-4. Three micron 
sections were cut and allowed to adhere to slides in the cold for 5 
days. The sections were incubated for 60 min in Burstone's complete 
media (Pearse, 1968) containing Napthol AS-BI phosphate as substrate 
and Red-violet LB diazonium salt as the capture agent in 0.1 M Trizma 
buffer (pH 8.5). Control sections·were incubated without substrate. 
The last third of the specimens and samples of the proximal 
tibiae were prepared for demonstration of tartrate resistant acid 
phosphatase activity using a modified Cole and Walters (1986) method 
(sections were not decalcified). In brief, samples were immediately 
fixed in cold 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) 
with 7% sucrose for 3 hr., dehydrated in ascending concentrations of 
cold acetone and embedded in JB-4. Three micron sections were cut and 
allowed to adhere to gel-coated slides in the cold for 5 days. The 
sections were stained for TRAP activity using 50 mM L(+)-tartaric acid. 
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Control sections were incubated without substrate. Alternate sections 
were stained for mineral content using the von Kossa technique. 
The level or intensity of the TRAP reaction product in multinu-
cleated giant cells located along the bone surface was analyzed using a 
computerized image analysis system, Princeton Gamma Tech System 4+ 
image processor, DEC PDP 11/73 and PGT Imagecraft software. The tech-
nique is described in detail in Chapter III. Comparisons were made 
among the average number of cells expressing different levels of TRAP 
activity within each hormone-treated implant type. Comparisons were 
also made between the average number of cells expressing high levels of 
TRAP activity for each hormone-treated implant types (mineralized, 
demineralized and composite), their appropriate controls and the aver-
age number of osteoclasts expressing high levels TRAP from the proximal 
tibiae. Statisitics were performed using the Dunn-Bonferroni t-test 
and Welch's t'W test for multiple comparisons (Wilcox, 1987). 
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RESULTS 
TRAP localization by this technique, results in a granular 
red-maroon reaction product nonuniformly distributed throughout the 
cytoplasm. Extracellular staining was also noticed along the bone 
particles and in the dense connective tissue, often near MNGCs. No 
differences were noticed among the MNGCs from each of the three hormone 
control implant groups. The cells from each control implant group were 
similar in morphology and TRAP reactivity indicating the vehicles had 
no effect on the parameters analyzed. 
The majority of the MNGCs from the mineralized implants exhib-
ited low levels or absence of TRAP reactivity, regardless of hormone 
treatment (Figures 1,2,3). Low level reaction product could be 
characterized by a diffuse pink staining throughout the cytoplasm (Fig. 
4). The reaction product was not often seen in granular form. These 
cells were in contact with the bone particles and often elongated in 
shape to cover the surface of the particle. Ultrastructural analysis 
revealed the area of the bone-cell interface was unremarkable in terms 
of membrane specializations (Fig. 5). Nuclei were usually linearly 
situated, parallel and at a distance from the bone surface. The 
non-opposing cell membranes could be found exhibiting nonspecific 
membrane ruffling. 
MNGCs stained with intense TRAP activity were found at the 
osteogenic site of the demineralized implant. Areas of osteogenesis 
were determined by the presence of cells exhibiting alkaline phospha-
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ease and von Kossa staining for mineralized matrix. Fourteen days 
represented the early stages of remodelling. There were areas of 
developing cartilage and mineralized matrix, which were covered by a 
layer of osteoblastic cells or scattered osteoclasts (Fig. 6). The 
osteoclasts were irregular in shape and made discrete contacts with the 
mineralized matrix. The multinucleated cells along with some 
mononuclear cells stained strongly for TRAP. Only the multinucleated 
cells in contact with the bone matrix were evaluated (Fig. 7). In some 
cells the reaction product was unevenly distributed and localized in 
the cytoplasm adjacent to the areas of bone contact. Treatment with 
l,25(0H) 2D3 and CT showed no major changes in development of the 
osteoclasts at this ectopic site. CT seem to be more stimultory in 
terms of osteogenesis. PTH administration however, completely 
inhibited osteogenesis and osteoclast development in the demineralized 
implant samples. The PTH treated implants elicited mononuclear cells 
with little TRAP activity to the implant site. MNGCs similar to those 
seen at the mineralized site of other implants were not seen. Half of 
the samples from the l,25(0H) 2n3 treated animals did not generate an 
osteogenic site. In the l,25(0H) 2D3 samples that were osteogenic and CT 
treated demineralized implants, normal bone remodelling occurred. 
Ultrastructural analysis of the MNGCs from l,25(0H) 2n3 and CT treated 
demineralized implants revealed normal osteoclast morphology. Cells in 
contact with the bone surface exhibited abundant mitochondria, clear 
zones and ruffled borders. The nonopposed surface did not exhibit 
intense membrane ruffling as seen in the MNGCs from the mineralized 
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implants. 
The composite implant was able to elict a mixed population of 
MNGCs based on morphological and histochemical criteria. Von Kossa 
staining revealed most MNGCs were in contact with mineralized parti-
cles. Osteogenesis occurred in one l,25(0H) 2D3 treated implant and one 
CT treated implant. In these implants, the MNGCs exhibited intense 
TRAP activity and ruffled borders and resembled those from the osteo-
genie demineralized implants. Most MNGCs from the hormone-treated 
composite implants resembled those from the mineralized implants, 
exhibiting little if any TRAP reactivity and no ruffled borders (Fig. 
8). However, a subpopulation, which stained more intensely for TRAP 
and exhibited osteoclastic features including ruffled borders were also 
present (Fig. 9). The number of these cells increased significantly 
(p<.05) with l,25(0H) 2o3 treatment (Fig. 1). These cells, could be 
identified at the light microscopic level, on the basis of smaller 
size, discrete contacts with the bone surface and membrane special-
izations at the bone/cell interface. 
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DISCUSSION 
This investigation was designed to assess the effects of local 
hormone infusion on the morphology and enzyme expression in populations 
of multinucleated cells elicited by mineralized, demineralized and 
composite bone implants. Each implant elicited a unique cellular 
response, evidently dependent on the presence or absence of mineralized 
matrix. The effects of the hormones on cells elicited by the mineral-
ized implants were of particular interest because infusion of the 
stimulators of bone resorption was an attempt to generate osteoclasts 
at an ectopic site. In previous investigations by this and other 
laboratories, osteoclasts have not been elicited by mineralized matrix, 
as claimed by Glowacki and Cox (1986). Gowacki and Cox stated the only 
stimulus necessary for osteoclast development was the implanted 
mineralized matrix. I do not deny the importance of mineralized matrix 
as a stimulator of osteoclast development and function and as the 
substrate for these cells. However, in this investigation, the 
presence of the mineralized matrix alone or together with local infu-
sion of either PTH or l,25(0H) 2D3 , did not promote the development of 
osteoclasts at the site of ectopically implanted mineralized bone 
matrix. Instead, as documented by the studies of Walters and Schneider 
(1985, 1988) and Popoff and Marks (1986) the implanted mineralized 
matrix elicited an inflammatory response characterized by the infiltra-
tion of osteolytic, non-osteoclastic, slightly TRAP positive MNGCs. At 
the light microscopic level, the location and morphology of these MNGCs 
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are similar to those of osteoclasts however, ultrastructurally, ruffled 
borders, the hallmark morphological feature of the osteoclast, were not 
seen in treated or control implants. 
PTH and l,25(0H) 2D3 have been shown to stimulate osteoclastic 
formation and function. PTH-stimulated bone resorption is associated 
with increased synthesis and secretion of hydrolytic enzymes including 
TRAP and expansion of the ruffled border (Vaes, 1965, 1968; Miller, 
1978; Miller et al.,1984). Like other stimulators of bone resorption, 
PTH and l,25(0H) 2o3 do not affect the osteoclast directly but are 
thought to act indirectly via the osteoblast (Rodan and Martin, 1981; 
Chambers et al., 1985; McSheehy and Chambers, 1986a). In the mineral-
ized implants the absence of alkaline phosphatase staining indicates 
the lack of osteoblasts and osteogenesis at this site. The ineffec-
tiveness of PTH and l,25(0H) 2o3 may be due to the lack of osteoblasts 
at the site. However, it has been shown that other cells like lympho-
cytes, which are present at the site of implantation, have receptors 
for these hormones and may play a role as modulator of osteoclast 
development and function (Whitfield et al., 1970). 
CT has also been shown to be a direct modulator of bone activ-
ity, specifically as an inhibitor of osteoclast activity (Nicholson et 
al., 1986; Chambers et al., 1986). Chambers and Magnus (1982) showed 
the quiescent effects on isolated osteoclasts and no effects on iso-
lated osteoblasts, peritoneal macrophages or inflammatory giant cells. 
By the parameters evaluated, there was no effect of CT on the MNGCs 
elicited by the mineralized bone matrix implant. 
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The question still remains, are osteoclasts or their precursors 
present at the site of the implanted mineralized matrix? I believe 
that osteoclasts are not present and cannot be recruited to this site, 
therefore, the hormones would be ineffective in stimulating an increase 
in TRAP activity or expression of osteoclastic morphology. The osteo-
tropic hormones have not been shown to affect non-osteoclastic osteo-
lysis which is characteristic of some inflammatory pathologies 
(Chambers and Magnus, 1982). The data from this investigation indicate 
osteoclasts are not present either with or without local infusion of 
osteotropic hormones at the site of the mineralized bone implant. 
Osteoclasts can be elicited at the site of ectopically implanted 
demineralized matrix after the formation of bone. The demineralization 
process unlocks the osteoinductive potential of bone morphogenic 
protein, which initiates the complex cascade of bone formation (Urist 
and Strates, 1970). Reddi and Huggins (1972) described the osteoinduc-
tive nature of the demineralized bone matrix as transformability, 
because the matrix, the factors present in it and/or released by it, 
induces fibroblasts to undergo differentiation toward the osteoblast 
phenotype. Osteogenesis does not occur at the site where mineralized 
bone is implanted. 
The phase of the osteogenic cascade relevant to this 
investigation is remodelling. The implants were removed at 14 days to 
correspond to previous studies and to the lifetime of the pumps. The 
experiments were designed so that the hormone would be infused from the 
time of implantation. At 14 days, the remodelling phase had just 
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begun. Osteoclasts were present and demonstrated ruffled borders and 
intense TRAP activity. The effect of the hormones was therefore on the 
process of osteoclast recruitment and subsequent function. Mononuclear 
TRAP positive cells were present in the area of remodelling and these 
cells may be osteoclast precursors. There was a marked difference in 
the multinuclear cells elicited by the demineralized and mineralized 
matrices. The osteoclasts from the demineralized implant were smaller 
in size and made discrete contacts with the newly mineralized bone. 
This was in sharp contrast to the MNGCs from the mineralized implants 
which were large cells that almost totally surrounded the particles. 
All osteoclasts from controls, l,25(0H) 2n3 and CT treated implants 
exhibited moderate to high TRAP activity and ruffled borders. 1,25 
(OH) 2D3 and CT have opposing effects on bone resorption, but they may 
have similar, stimulatory effects on bone formation (Parfitt et al., 
1984; Farley et al., 1988; Weiss et al., 1981). I saw no change in 
TRAP activity since the contol osteoclasts were classified at the 
highest level. To determine if a change was present, the scale of 
enzyme activity would have to be reevaluated. 
The PTH treated demineralized implants failed to generate either 
an osteogenic or inflammatory reaction. Few MNGCs were seen at the 
implant site indicating again, the presence or absence of the mineral-
ized matrix had profound effects on eliciting an inflammatory reaction. 
PTH has been shown to decrease bone formation by inhibiting synthesis 
and secretion of matrix proteins, and alkaline phosphatase (Kream et 
al., 1980; Majeska and Rodan, 1982). Chronic high doses of PTH have 
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been shown to have an inhibitory effect on bone formation, which may 
explain what was seen in this investigation (McGuire and Marks, 1974; 
Tam et al., 1982) . 
Mineralized matrix is essential for osteoclast function. 
Osteoclasts preferentially chose mineralized matrix as a substrate 
although it has been shown they are capable of resorbing a nonminer-
alized surface (Reid 1986). Krukowski and Kahn (1982) grafted parti-
cles of devitalized, mineralized bone; devitalized, demineralized bone; 
hydroxyappatite and egg shell onto chorioallantoic membranes, and 
showed the only substrate to elicit osteoclast-like giant cells was the 
mineralized bone. They concluded factors responsible for osteoclast 
differentiation lie within the matrix, specifically associated with the 
mineral phase; in response to mineralized matrix, osteoclast can 
differentiate at an ectopic site. This study does not substantiate the 
conclusion from Krukowski and Kahn (1982). The role of the live, 
mineralized matrix in osteoclast development is emphasized in the fetal 
metatarsal coculture system. Osteoclasts developed when marrow mononu-
clear cells were cocultured with these bone rudiments but not with 
devitalized fetal metatarsals or devitalized, mineralized bone parti-
cles (Burger et al., 1982; Burger et al., 1984). Mineralized matrix is 
not the only signal for osteoclast formation. 
In the composite implant, the dominant reaction to the bone 
particles was an inflammatory response, similar to that seen in the 
purely mineralized implant. This response is probably due to the 
presence of the mineralized matrix since an inflammatory response is 
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seldom seen when demineralized bone is implanted. The ability of this 
type of implant to elicit osteoclastic cells seems to be more dependent 
on the presence of the demineralized bone matrix than the mineralized 
matrix. As in the case with bone morphogenic protein, the deminerali-
zation process unlocks its inductive capabilities. Other cytokines 
which stimulate osteoclastogenesis may also be associated with the 
mineralization phase of the matrix and are therefore incapable of being 
released. These cytokines which can be released from the demineralized 
matrix may influence osteoclast development directly or indirectly. In 
the purely demineralized bone implants osteoclasts were not present 
until mineralized matrix was formed indicating that mineralized matrix 
may be needed for recruitment, maturation and/or activation. In the 
composite implant the mineralized matrix is already present and inhib-
its the osteoinductive potential of the demineralized matrix simply by 
its presence or by the inflammatory reaction it elicits. However, just 
because osteogenesis did not occurred, does not mean that the deminer-
alized matrix had no effect on the cells at the implant site. The only 
parameter of osteogenesis that was evaluated in this investigation was 
alkaline phosphatase. The demineralized matrix in the presence of the 
mineralized matrix may not induce osteogenesis but it may continue to 
cause some cellular differentiation or expression of factors to elicit 
osteoclasts. This type of implant may serve as a model of pathological 
bone loss because it is able to elicit osteoclasts and inflammatory 
phagocytes capable of osteolysis. Both may play equally important 
roles directly or indirectly, in bone destruction. 
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l,25(0H) 2D3 was the only hormone which affected the TRAP 
activity of the MNGCs in the composite implant. The number of intense-
ly staining cells increased with l,25(0H) 2D3 treatment. From this 
investigation, I am unable to determine if (1) l,25(0H) 2D3 stimulated 
an increase in TRAP expression in cells which had previously expressed 
low levels of the enzyme or, (2) more cells that express high levels of 
TRAP were recruited to the site. Recruitment rather than of induced 
expression seems more likely the case because more TRAP positive 
mononuclear cells were seen with l,25(0H) 2D3 infusion. If l,25(0H) 2D3 
acted as a fusogen, more TRAP positive multinucleated cells may have 
been formed. Few if any osteoclasts analyzed expressed low levels of 
TRAP indicating, a high level of TRAP activity is normally seen in 
osteoclasts. 
The purpose of this investigation was to determine if local 
hormone infusion could influence the recruitment of osteoclasts to 
ectopic bone implants. Osteoclasts could not be recruited to the site 
of the mineralized bone particle implants with or without stimulation 
from l,25(0H) 2o3 or PTH. Osteoclasts were recruited for remodelling of 
the new bone in the demineralized implants except in the PTH treated 
implant, where osteogenesis and subsequent remodelling were absent. 
l,25(0H) 2D3 had a stimulatory effect on the number of MNGCs expressing 
TRAP activity in the composite implants. Osteogenesis was absent 
except in one l,25(0H) 2D3 treated sample and one CT treated sample. CT 
had no effect on the MNGCs elicited by any of the implants in this 
model system. 
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Although a number of other parameters could have been included 
to evaluate the hormonal effects on formation of MNGCs, the cellular 
populations elicited by the different bone implants, osteogenesis and 
remodelling, this study was limited to the morphology and histochem-
istry of the MNGCs. The results indicate a stimulatory role for 1,25 
(OH) 2n3 in the development of osteoclasts in the composite implant. 
This study also indicates that demineralized matrix may function as a 
storehouse of inducing factors which may affect osteoclast development 
either directly or indirectly. The matrix is important in the 
development and function of bone cells. 
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Figure 1. 
TRAP expression in MNGCs from mineralized, demineralized and 
composite bone implants (2 wks. post-implantation) and in situ 
osteoclasts from l,25(0H) 2n3 treated (T) and control (C) rats. 
TRAP expression scored as high level (++), moderate level (++) and 
absence (0) of reaction product. (mean ±SEM). 
a. mineralized (T) (++) significantly different than tibia 
(C) (++), p<0.05. 
b. mineralized (T) (++) significantly different than 
demineralized (T) (++), p<0.05. 
c. mineralized (T) (++) significantly different than 
composite (T) (++), p<0.05. 
d. compostie (T) (++) significantly different than 
composite (C) (++), p<0.05. 
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Figure 2. 
TRAP expression in MNGCs from mineralized, demineralized and 
composite bone implants (2 wks. post-implantation) and situ 
osteoclasts from PTH treated (T) and control (C) rats. TRAP 
expression scored as high level(++), moderate level (+), and 
absence (0) of reaction product. (mean ±SEM). 
a. mineralized (T) (++) significantly different than tibia 
- (C) (++), p<0.05. 
b. demineralized (T) (++) significantly different than 
demineralized (C) (++), p<0.05. 
c. demineralized (T) (++) significantly different than 
tibia (C) (++), p<0.05. 
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Figure 3. 
TRAP expression in MNGCs from mineralized, demineralized and 
composite bone implants (2 wks. post-implantation) and in situ 
osteoclasts from CT treated (T) and control (C) rats. TRAP 
expression scored as high level(++), moderate level (+), and 
absence (0) of reaction product. (mean ±SEM). 
a. mineralized (T) (++) significantly different than tibia 
(C) (++), p<0.05. 
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At 14 days, MNGCs elicited by a mineralized bone implant from a 
1,25 Dihydroxyvitamin n3 treated rat: 
Figure 4. 
Low levels of TRAP are demonstrated in MNGCs (arrows) adjacent to 
mineralized bone particles (b). x413 
Figure 5. 
MNGC in contact with a mineralized bone particle. Note the 
absence of membrane specialization at the cell-bone interface. 
xl2000 
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At 14 days, osteoclasts at demineralized bone implant from a 
calcitonin treated rat: 
Figure 6. 
Osteoclasts (arrows) are present along the newly mineralized 
matrix (b) and remodelling is in progress at the osteogenic site. 
x438 
Figure 7. 
Osteogenic site stained for TRAP reaction product. Osteoclasts 
(arrows) along the bone (b) containing high concentrations of TRAP 
reaction product. x413 
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At 14 days, MNGCs elicited by composite bone implant from a 
parathyroid hormone-treated rat: 
Figure 8. 
MNGCs (arrows) at or near the bone (b) surface demonstrating a 
range of TRAP reaction product intensities. In the highly TRAP 
postive cells note the distribution of TRAP reaction product and 
the intensity of the enzyme along the bone-cell interface. x660 
Figure 9. 
MNGC in contact with the bone (b), demonstrates a clear zone (c) 
and ruffled border (rb), membrane specializations of osteoclasts. 
x7500 
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CHAPTER VII 
DISCUSSION 
The skeleton defines the shape of an organism. It facilitates 
locomotion, protects vital organs and functions as a storehouse for 
calcium and phosphate. It is under constant reconstruction. Although 
the gross shape remains relatively constant throughout adult life, the 
matrix microstructure is being destroyed and replaced by a complex se-
quence of cell-mediated events. The osteoclast is mainly responsible 
for the destructive phase of the remodelling process. Because of its 
life-threating potential, the osteoclast is highly regulated, mainly 
through the osteoblast, the effector cell of bone formation . The roles 
of the osteoblast in both bone formation and resorption provides a link 
between the two interdependent processes. Whether the osteoblast is 
necessary for osteoclast differentiation and function is one question 
addressed by the studies of this dissertation. 
In this dissertation, the bone implant system, using three 
different matrix preparations, has provided three models to study the 
events in normal and pathological bone cell function. The focus of the 
studies have been on the bone resorption process and whether any or all 
of the bone implants would provide a good model to study osteocla st 
differentiation and function. 
TRAP and classic morphological features were used to identify 
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osteoclasts in these implant studies. TRAP has been accepted as a 
marker of osteoclast function and has been extensively used to identify 
the differentation of osteoclasts in vivo and in vitro. It is easily 
demonstrated and seemed to be a reliable marker. However, the 
specificity of this form of acid phosphatase to the osteoclast has been 
questioned after its demonstration in other cells. Its specificity be-
came particularly important since TRAP was being used to assess the 
differentiation of osteoclasts in bone marrow cultures where nonosteo-
clastic multinucleated cells which are capable of TRAP expression were 
also present. An objective method of quantitation had never been 
established to determine if a particular level of TRAP reaction product 
was specifically associated with the osteoclast. A specific level of 
enzyme expression could be used to identify osteoclasts instead of the 
presence or absence of the enzyme. From the developement of one such 
method of assessment, described in detail in Chapter III, a high level 
of TRAP reaction product was determined to be a characteristic of 
osteoclast. The osteoclasts consistently expressed high levels of TRAP 
reaction product. With the ability to standardize the method of analy-
sis and determine a level which could characterize the osteoclast, TRAP 
could again be considered an effective criteria for osteoclast identi-
fication in normal and experimental situations. 
Three different bone matrix preparations were used to elicit 
three different responses. Implantation of mineral bone particles had 
been shown to elicit an osteolytic response. It seemed possible that 
osteoclasts may be recruited to the site to remove bone matrix since 
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mineralized bone stimulates the formation and is the specific substrate 
of osteoclasts, but it seemed equally possible that the bone implant 
would elicit an inflamatory response like other particulate foreign 
matter and be removed by phagocytic cells. Evidence has previously 
been reported to support both the presence of osteoclasts in one case 
and phagocytic cells in another. Results from this study indicate the 
lack of osteoclasts at the site of mineralized bone implants. The 
multinucleated giant cells present 14 days post-implantation which 
resemble osteoclasts in some ways, fail to exhibit ruffled borders or a 
high level of TRAP reaction product. 
One explanation for these findings is that the devitalized 
mineralized bone particles do not provide the appropriate cues neces-
sary for the recruitment and differentiation of osteoclasts at this 
ectopic site. Mineralized bone has been shown to be a stimulator of 
osteoclast formation and function however in this model, the presence 
of mineralized bone alone is insufficient to promote osteoclast forma-
tion. Burger et al. (1984) have suggested live bone, particularly the 
osteoblasts population, is necessary for the differentiation of osteo-
clasts. Others have also shown that osteoblasts are required for 
osteoclast formation and activation in vitro (McSheehy and Chambers, 
1986; Rodan and Martin, 1981). It is evident osteoclasts are dependent 
on the physical and cellular microenvirorunent in which they function. 
Absence of factors at this subcutaneous site, which are normally pres-
ent in the microenvirorunent of bone, may have limited the recruitment 
of mononuclear precursors, their fusion, expression and/or function as 
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mature osteoclasts. 
Another explanation for the findings is that the inflammatory 
response is the dominant response inhibiting the ability of the matrix 
to stimulate osteoclastic recruitment. The bone particles are almost 
completely surrounded by multinucleated giant cells at 14 days, which 
would prevent exposure of the matrix to osteoclasts. If osteoclasts 
were present, they would be in competition for contact with the bone 
matrix particles. 
In the final attempt to stimulate the recruitment of osteoclast 
precursors and/or differentiation of osteoclasts at this ectopic site, 
stimulatory hormones and interleukin 2 (IL-2) was infused. Direct, 
constant infusion of 1,25 dihydroxyvitamin n3 (l,25(0H) 2D3), parathy-
roid hormone (PTH) and IL-2 for 14 days failed to produce osteoclasts 
at the mineralized bone implant. If osteoclasts had been present at 
the site but were unable to express ruffled borders or a high level of 
TRAP, the hormones may have been able to stimulate their expression. 
If osteoclasts were not present at the implant site, the hormones would 
be ineffective. With these results from the hormone studies, it is 
unlikely that the devitalized, mineralized implant with or without 
stimulation, is able to recruit precursors or stimulate formation of 
osteoclasts. Use of this system for the study of osteoclast recruit-
ment and function would be inappropriate. This system however, could 
be used to evaulate the potential role of macrophages and macrophage-
derived cells in the inflammatory osteolytic process. Mononuclear 
phagocytes have been identified at sites of inflammarntory osteolysis 
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and have been shown to be active participants. Their direct contribu-
tion to the osteolytic process and their role in health and disease may 
be significant. The mineralized matrix implant may be the appropriate 
model to analyze the potential of the nonosteoclastic populations in 
matrix degradation and develop means to control this inflammatory bone 
loss. 
Implantation of a demineralized matrix elicits an osteogenic 
response and has been extensively used to study the process of bone 
formation. The amazing ability to stimulate the differentiation of 
cells responsible for the synthesis of a mineralized bone matrix at an 
extraskeletal site reveals the undifferentiated state of mesenchymal 
cells, even in the adult organism, and the impact of the matrix on 
these cells. The sequence of events is highly predictable and is simi-
lar to endochondral bone formation. By day 14 post-implantation, 
osteoclasts are recruited to remodel the mineralized matrix which would 
indicate this system a model appropriate for the study of both bone 
formation and resorption. The appearance of osteoclasts at the site of 
the deminerailzed implants, expression of high levels of TRAP and ruf-
fled borders were expected. The data from the demineralized implants 
were in aggreement with earlier studies however, the morphology and 
histochemistry of the osteoclast had never been the focus of attention. 
The differences between the osteoclasts recruited to this ectopic site 
with the multinucleated cells recruited to the mineralized site further 
reinforced the conclusions that the mineralized implant could not be 
used as a model for osteoclastic bone resorption. 
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PTH was the only hormone that affected the ability of the demin-
eralized implant to recruit osteoclasts by inhibiting its osteoinduc-
tive capacity. Since the osteoclasts had been expressing high levels 
of the enzyme without hormone treatment, it was difficult to conclude 
if the hormones enhanced TRAP expression. The ability of the deminer-
alized implant to recruit osteoclast precursors and stimulate their 
differentiation, and the potential ability to modulate these responses 
again indicates the ectopic bone implant system may be a useful model 
to study osteoclastic formation and function. 
The results from the composite implant system proved to be the 
most interesting of the three implants. The mixture of mineralized and 
demineralized bone matrices produce a nonosteogenic, inflammatory re-
sponse. The recruited cell population was similar to that from the 
mineralized implant except for a minor population expressing high 
levels of TRAP and membrane specializations reminiscent of ruffled 
borders. The dominant response as seen in the mineralizd implant is 
the inflammatory reaction. In this case, the presence of the mineral-
ized matrix and/or the inflammatory cells elicited by it, may inhibit 
osteogenesis. Even though there are no signs of bone formation, as 
monitered by the expression of alkaline phosphatase, it cannot be 
concluded that the demineralized bone particles had no effect. The 
results from the other 2 types of matrix implants indicates the 
demineralized implant may have more of an effect on bone cell dif feren-
tiation than the mineralized matrix. Urist and Strates (1970) stated 
the demineralization process allows the release of factors that stimu-
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late bone formation. It is now known that the bone matrix is a store-
house for factors that affect both bone formation and bone resorption 
and stimulators of the bone resorption process may also be freed by the 
extraction of the mineral phase. The signal for osteoclast recruitment 
and/or differentiation may be weak which would explain the small number 
of osteoclasts that were identified. 
Treatment with l,25(0H) 2n3 and IL-2 was shown to increase the 
expression of the enzyme while all treatments continued to produce 
cells with osteoclastic characteristics. Unlike PTH and calcitonin 
(CT) which are effectors of osteoclastic function, l,25(0H) 2D3 is 
thought to be an effector of osteoclast differentiation, which may 
indicate in this investigation, that l,25(0H) 2D3 is stimulating the 
formation of osteoclasts at this ectopic site. IL-2 may also have a 
direct or indirect effect on osteoclast formation. 
In order to effectively study the formation and function of 
osteoclasts, investigators are in search of the perfect model system. 
One in which an isolated pure population of osteoclasts can be used for 
study. Attempts have been made to preferentially induce the formation 
of osteoclast in vitro and to isolate mature osteoclasts from the sur-
face of the bone. These systems have provided important information, 
however they are far from ideal. The bone implant system may provide an 
in vivo approach to the study of bone cell function. From its uncer-
tain hemopoitetic origins, to the complexitiy of its function and 
interactions with other cells, the osteoclast is a challenging subject 
of intriguing investigation. 
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In summary, the work of this dissertation has: 
1. developed an objective method to quantitate intracellular TRAP 
activity and determined that there is a level of expression 
specific to the osteoclast 
2. provided evidence to reject the use of the mineralized matrix 
implant as a model for bone resorption due to the inability to 
generate osteoclasts at the site with or without stimulation 
3. provided evidence to substantiate the presence of osteoclasts at 
the site of the demineralized bone implant and propose the use 
of the system to study the osteoclast 
4. introduce the composite implant as a model for inflammatory bone 
loss due to the presence of osteoclasts and inflammatory giant 
cells. 
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APPENDIX A 
A MORPHOLOGICAL, HISTOCHEMICAL AND FUNCTIONAL COMPARISON OF 
THE CELLS ELICITED BY MINERALIZED BONE IMPLANTS 
24 HOURS AND 14 DAYS POST-IMPLANTATION 
168 
Cells recruited to the site of ectopically implanted mineralized 
bone particles can be characterized functionally as osteolytic cells 
but morphologically they do not demonstrate the hallmarks of active 
osteoclasts. Pellets of mineralized bone powder (particle size 75- 250 
urn), were implanted subcutaneously on the dorsal body wall of young 
adult rats. Two weeks post-implantation, the connective tissue 
encapsulated pellets were removed and processed for morphological, 
histochemical and functional analyses. Implanted pellets removed 24 
hours post-implantation served as controls. At one day after implanta-
tion, the bone particles were surrounded by mononuclear inflammatory 
cells, which exhibited no TRAP activity (Fig la). Ultrastructurally, 
the mononuclear cells also failed to exhibit ruffled borders, the 
hallmark morphological feature of the osteoclast (Fig lb). In the 2 
week implant samples, the bone particles were surrounded by large 
multinucleated cells. Unlike normal osteoclasts which express intense 
TRAP activity, the multinucleated cells of the 2 week implants 
expressed weak or total absence of TRAP activity (Fig 2a). Ultrastruc-
turally, these cells were seen contacting the bone particles however, 
ruffled borders or other membrane specializations were absent (Fig. 
2b). To evaluate the functional capabilities of these multinucleated 
cells, the per cent surface area occupied by bone and the number of 
particles per field were determined. Three micron sections were 
stained with von Kossa for mineral content. The total surface area 
occupied by the bone particles, 24 hrs. post-implantation versus 2 wk. 
169 
post-implantation, was calculated using the Bioquant software package, 
run on an Apple 2 computer. The number of bone particles per field was 
also calculated. The implants exhibited a 20% reduction in bone sur-
face area (p<0.05), and a 38% reduction in particles per field compared 
to controls (p<0.05). In conclusion, although these cells appear to be 
osteolytic, they do not appear to be osteoclasts. These results indi-
cate the implantation of mineralized bone promotes a response similar 
to that elicited by other particulate foreign substances. It does not 
differentially recruit osteoclasts and exposure of mineralized matrix 
may be one of many signals needed to stimulate osteoclast recruitment, 
differentiation, and/or function. 
170 
Figure 1. 
24 hrs. post-implantation of mineralized bone particles: 
a. Lack of MNGCs at the site of the implant at this early time 
point. Lack on TRAP reactivity in mononuclear cells present. 
x425 
b. Mononuclear cell in contact with a bone particle (b). xl2000 
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Figure 2. 
2 wks. post-implantation of mineralized bone particles: 
a. Lack of TRAP reactivity in MNGCs (arrows) in contact with 
mineralized bone particles (b). x425 
b. MNGC in contact with a bone surface (b). Note the absence of 
membrane specializations. xlOOOO 
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APPENDIX B 
ELEMENTAL ANALYSIS OF A COMPOSITE IMPLANT AS·DETERMINED 
BY ENERGY DISPERSIVE SPECTROSCOPY 
175 
Elemental analysis for calcium, phosphorus and zinc superimposed 
on a scanning electron micrograph of a composite implant prior to 
implantation as determined by energy dispersive spectroscopy (EDS). 
Particles (75-250 um diameter) were prepared per Material and Methods, 
Chapter IV, coated with gold and analyzed using the Princeton Gamma 
Tech System 4+ and JEOL JSM-840A scanning electron microscope. The 
horizontal line (at arrow) represents the scan line for the collection 
of X-ray counts. The superimposed spatial distribution of counts 
within the energy window for phosphorus (a) and calcium (b) indicates 
high levels of these elements in the bone particle (Bl) low levels in 
bone particle (B2). The spatial distribution of counts within the 
energy window for zinc was used to assure the changes in above counts 
were unrelated to the geometric profile of the particles at the level 
of the scan line. 
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